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Abstract 
 
Background: Recurrent Miscarriage (RM) is defined as two or more consecutive 
pregnancy losses before 20th week of gestation, it is one of the most common 
pregnancy complications, affecting up to 2–4% of women of reproductive age. Several 
contributing factors have been identified in the risk of recurrent miscarriages, such as 
genetic defects, the immune system, endocrine and anatomical systems. The etiology in 
approximately 50% of cases of RM is unknown, but it has been assumed that a 
proportion of these recurrent pregnancy losses may be due to immunological reasons. 
During normal pregnancy, there is a cooperative interaction between the maternal 
immune system and fetal antigen, the failure of this immune system adaptation causes 
alloimmune rejection of the fetus, leading to loss of pregnancy. 
After encountering the antigen, T helper (Th) precursors differentiate into functionally 
Th1 and Th2 cells, with unique patterns of cytokine production. Cytokine production 
levels are partly under genetic control, and their gene expression can be changed by 
nucleotide variation. Several studies have shown that cytokines play a major role in 
reproductive phenomena, where the predominant response of Th2 has been associated 
with normal pregnancy, and the Th1 response has been linked to pregnancy failure. The 
expression of pro-inflammatory cytokines in the uterus such as IL-17, TNF and IL-6 has 
been associated with fetal loss. Anti-inflammatory cytokines such as IL-10 appear to 
protect against inflammation-induced miscarriage and protect against abortion caused 
by inflammation. 
Objective: To investigate the association of RM with polymorphisms of an anti-
inflammatory IL-10 (-592 A/C, -819 C/T), and two pro-inflammatory IL-17A, IL-17F 
and IL-6 (174 C/G) cytokine genes in RM compared to normal Palestinian women in 
the West Bank. 
Methods: This study included 107 women from different areas of the West Bank, ( 
Ramallah, Al-Khalil, Jerusalem, Bethlehem, Nablus, Tulkarem, and Jercho. 55 women 
with recurrent miscarriages without a specific cause, and 52 women who do not have 
any pregnancy-related risks. All samples were  analyzed by polymerase chain reaction 
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(PCR) targeting IL-10,IL-6, and IL-17 gene polymorphisms followed by RFLP, using 
specific restriction enzymes for each gene site 
Results: This study has proven a significant association of polymorphism in the IL10-
819 C/T, and increased frequency of recurrent miscarriage among Palestinian women 
(p=0,0009) and the lack of association between polymorphisms in IL10-592C / A, IL6-
174G / C, IL-17, and recurrent miscarriage in the studied group. 
Conclusions: There is not only one genetic factor, but possibly several that are involved 
in the abortion disease etiology. There are about 50% are idiopathic factors. If the 
relationship between genetic factors and immune system disorders is explained, genetic 
polymorphisms as the one that is studied may represent markers for choice of 
therapeutic options and for counseling patients with repeated spontaneous abortions. 
There are significant differences in the results of previous studies conducted in different 
regions of the world on this subject, these discrepancies may be explained by ethnic 
differences of the study groups as well as the variation in number of the subjects that are 
included in the research  
To the best of our knowledge, this was the first report in the West Bank at Palestine that 
examines the relationship between IL-10, IL-6, and IL-17 gene polymorphisms and 
spontaneous abortion, which may be considered as supportive of previous studies in the 
same field. However, the true mechanism of this relationship remains unknown and 
requires more investigation.  
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Chapter One  
Introduction 
 
1.1 Background 
 
Recurrent miscarriage (RM) is defined as two or more consecutive pregnancy losses 
before 20
th
 week of gestation. It is one of the most common pregnancy complications 
affecting up to 2–4% of women of reproductive age (Zidan, Rezk, Alnemr, & Moniem, 
2015). Approximately 1% of all women trying to conceive have RMs. When RM is 
defined as two previous miscarriages, the proportion rises to 5% (Alalaf, 2012). This is 
a devastating problem, particularly to Palestinian families who are fond of having large 
families. Several identified risk factors, such as genetic, immune, endocrine, anatomical 
and infective defects, have been postulated to contribute to the risk of RM (Branch, 
Gibson, & Silver, 2010). The aetiology of RM in approximately 50% of cases of is 
unknown. However it has been postulated that a proportion of these repeated pregnancy 
losses may be due to various immune causes (Laird et al., 2003). 
 
During normal pregnancy, there is cooperative interaction between maternal immune 
system and fetal antigen, in which failure of the immune system adaptation leads to 
alloimmune rejection of the fetus resulting in loss of pregnancy (Kumar, 2014) 
After encountering the antigen, T helper (Th) precursors differentiate into functionally 
T-cell lineages, including Th1 and Th2 cells, with unique patterns of cytokine 
production (Mosmann & Sad, 1996). Cytokine production levels are partly under 
genetic control, and their gene expression can be changed by nucleotide variation. 
Several studies have shown that cytokines play a major role in reproductive phenomena, 
where Th2- dominant response has been associated with normal pregnancy, and Th1 
response has been related to pregnancy failure (Alkhuriji, Alhimaidi, Babay, & Wary, 
2013). 
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Enhanced uterine expression of pro-inflammatory cytokines such as tumor necrosis 
factor (TNF), interferon-gamma (IFN-γ), interleukin (IL)-1β, and IL-6 has been 
associated with embryo loss (Haddad, Duclos, Antecka, Lapp, & Baines, 1997). Anti-
inflammatory cytokines such as IL-10 appear to protect against inflammation-induced 
miscarriage (Robertson, Care, & Skinner, 2007). It is generally accepted that a 
successful pregnancy is dependent on a shift away from Th1-type and a bias towards 
Th2-type immune responses (El‐Shazly, Makhseed, Azizieh, & Raghupathy, 2004) 
 
IL6 is a multifunctional cytokine with pivotal roles in the inflammatory response and in 
directing T cell differentiation in adaptive immunity. IL6 is widely expressed in the 
female reproductive tract and gestational tissues, and exerts regulatory functions in 
embryo implantation and placental development, as well as the immune adaptations 
required to tolerate pregnancy (Prins, Gomez-Lopez, & Robertson, 2012). A common 
C/G polymorphism located within the IL-6 gene promoter at nucleotide position 174 bp, 
upstream from the start site of transcription, has been reported to affect IL-6 expression 
and may contribute to miscarriage (Jasper, Tremellen, & Robertson, 2007). However 
the predictive value of IL-6 for pregnancy outcome remains unclear. 
IL 17 a pro-inflammatory cytokine, it is predominantly produced by distinct subset of T 
helper cells (Th17) (Harrington et al., 2005). Th17 cells are known to be involved in the 
pathogenesis of autoimmune and inflammatory diseases, immunological rejection of 
non-self tissue and may play role in the pathogenesis of RM (Fu, Tian, & Wei, 2014). 
Interleukin-10 (IL-10), defined as a pleiotropic anti-inflammatory cytokine, is produced 
by activated Th2 cells, B cells, monocytes and macrophages. (IL-10) promotes 
embryonic development by maintaining the maternal–fetal tolerance (Wang, Hao, & 
Lin, 2011). The IL-10 gene is located on chromosome 1q31–q32 region, of which the 
promoter is highly polymorphic, Many single-nucleotide polymorphisms (SNPs) were 
reported in the proximal at position−1082A/G (dbSNP ID rs1800896), −819C/T 
(dbSNP ID rs1800871), and −592C/A (dbSNP ID rs1800872) regions of IL-10 gene 
(Chaouat et al., 2002). 
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Study Justification 
Spontaneous recurrent miscarriages represent an important medical problem. Numerous 
researches have investigated the causes of abortion disease. However, in a significant 
percentage of patients, the exact cause of spontaneous abortions could not be identified. 
Immunological factors play an important role in execution and the physiological 
evolution of pregnancy. Few studies have been conducted to explain the relationships 
between the codifying genes for cytokines and the abortion disease.  
Research hypothesis  
There is an association between polymorphisms of two pro-inflammatory (IL-6 and IL-
17) and and anti-inflammatory (IL-10) cytokine genes with RM women in the West 
Bank/ Palestine. 
Study objective 
Considering the potential role of cytokines and cytokine polymorphisms in RM patients, 
the aim of this study was to investigate the association of RM with polymorphisms of an 
anti-inflammatory IL-10 (-592 A/C, -819 C/T), and two pro-inflammatory IL-17A, IL-
17F and IL-6 (174 C/G) cytokine genes in RM compared with normal pregnancy 
women in the West Bank. 
 
1.2 Literature review  
1.2.1 Recurrent miscarriage: 
Recurrent miscarriage (RM), which is defined as 2-3 or more consecutive pregnancy 
losses before 20 weeks, affects 0.5–2% of pregnant women (Ma, Xu, Wang, Xian, & 
Liu, 2012). RM is a genetically heterogeneous condition resulting from both maternal 
and embryonic regulating factors ( Rasti, Z., Nasiri, M., & Kohan, L. 2016) 
The exact pathophysiology of RM is still unclear. However, several etiological factors 
such as chromosomal abnormality, anatomic defects, hormonal problems, thrombophilic 
disorders, infections and immune system factors have been proposed to contribute to 
RM (Bahadori et al., 2014). 
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There are environmental factors contributing to recurrent miscarriage. Studies 
interesting about the effect of maternal cigarette smoking and exposure to 
environmental tobacco smoke on spontaneous abortion have been carried out in the past 
decades. Many studies indicated that a body mass index (BMI) of 24 or greater, passive 
smoking, and family history of miscarriage among women have an increased risk effect 
for RM (B. Y. Zhang et al., 2010).  
1.2.2 Recurrent miscarriage among Palestinian women: 
In the Palestinian community, the incidence of abortion is relatively high, estimated at 4 
-8% among women at the age of reproduction (Hussein, Darwish, & Shelbayeh, 2010). 
Hussein et al. have reported the association between factor V Leiden mutation and poor 
pregnancy outcomes among Palestinian women from the West Bank region of Palestine 
suffering from recurrent miscarriages with unknown cause, compared to control women 
with uncomplicated pregnancies and deliveries. Many studies have been conducted on 
the consideration of Thrombophilia as a significant factor that play a major role in 40-
60% of unexplained multiple miscarriages (Brenner et al., 1997). Inherited 
Thrombophilia is a multi-factorial disorder caused by inherited and acquired factors 
including mutations in genes that code for natural anticoagulants such as anti-thrombin, 
protein C, and protein S, or clotting factors like prothrombin and factor V (Walker, 
2000). 
The study of Hussein et al. provides evidence for the significant association between 
factor V leiden mutation and poor pregnancy outcome among the Palestinian 
population. The association of the mutation has an effect on miscarriages that happen 
after week 10 and becomes greater effect after 12 week of gestation. However, some 
early foetal losses reported in the study seem to have no association with factor V 
variant (Hussein et al., 2010). 
Another study has also been published in 2010 conducted to investigate the correlation 
between spontaneous (RM) and common polymorphisms in angiotensin-converting 
enzyme (ACE), plasminogen activator inhibitor 1 (PAI-1) and endothelium-derived 
nitric oxide synthase 3 (NOS3) genes among women experiencing RM in the Gaza Strip 
(Al Sallout & Sharif, 2010). There is a belief that Urokinase plasminogen activator, its 
receptor, and PAI-1 are control proteolysis and remodelling of maternal tissue during 
trophoblast invasion (Lockshin, 1999), (Floridon et al., 2000).  
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1.2.3 Immune cells and molecules in women with normal pregnancy 
and recurrent miscarriage: 
There is associated increase in tolerance promoting T regulatory cell (Treg) activity and 
a proportional decrease in the pro-inflammatory Th17-cell activity. Trophoblast acts as 
an allogenic tissue due to the parental genetic contribution during normal pregnancy 
(Fig 1.1). It induces an immunomodulatory effect, suppresses abortigenic maternal B 
and T cell responses leading to adaptation of the fetus (Y. K. Choi & Kwak‐Kim, 2008). 
The maternal immune tolerance is likely to be modulated by both adaptive and innate 
immunity during pregnancy. The natural killer cells − macrophage, dendritic cell and 
Treg cell − migrate and increase in the endometrium during the implantation window. 
Deletion of these cells has deleterious effects on implantation and placental 
development (Liang et al., 2015). There is an association between pregnancy loss and 
autoimmune phenomena such as the presence of antiphospholipid antibodies—Lupus 
anticoagulant and anticardiolipin antibody (Allahbadia & Allahbadia, 2003) 
Human chorionic gonadotropin (hCG) is also of very importance in the establishment of 
the early embryo in the endometrium. Its role has been defined in promoting 
angiogenesis and placentation and in recruiting and promoting maternal Treg cell 
function. B- hCG is important in maintaining pregnancy by promoting a down 
regulation of harmful maternal immunity (Kumar, 2014). 
 
Natural killer cells floading the uterus at the time of implantation carries receptors that 
interact with HLA-C, HLA-E on surface of trophoblast, triggering the secretion of 
cytokines that help trophoblast to invade or limit the extent to which it invades, (Fig1.1) 
(Bohiltea & Radoi, 2014a). The serum cytokine levels for adverse pregnancy outcomes 
such as preterm delivery, low–birth weight babies and small-for-date babies showed a 
significant difference only at the time of recruitment (Kumar, Begum, Prasad, 
Aggarwal, & Sharma, 2014), even  during early pregnancy, plasma levels of pro-
inflammatory cytokines are higher, while levels of anti-inflammatory cytokines are 
lower in women who miscarry than in those who have normal pregnancy (Alkhuriji et 
al., 2013). 
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Figure 1.1Maternal tolerance of the fetus. MHC II antigens and polymorphic MHCI antigens 
such as HLA-A and HLA-B are not expressed on trophoblasts of placental origin. By contrast, 
the invasive extravillous cytotrophoblast and endovascular trophoblast cell subsets express a 
unique subset of MHCI products, HLA-C and HLA-G. Debris from apoptotic or necrotic 
trophoblast cells is released into maternal peripheral blood and activates the maternal immune 
system. Subsequently, activated FOXP3+CD4+CD25+ TREG cells induce tolerance to specific 
fetal antigens by suppressing immune system activation (Tower, Crocker, Chirico, Baker, & 
Bruce, 2011) 
 
 
1.3.1 Cytokines: 
Cytokines are signalling, soluble proteins or glycoproteins, complex, pleiotropic group 
that are secreted by different immune cells, leukocytes and other cell types. They act as 
chemical communicators between cells, but are not effector molecules in their own 
right. Some can be expressed on the cell membrane, others are held in reservoirs in the 
extracellular matrix. Cytokines bind to specific receptors on the surface of target cells. 
These receptors are coupled to intracellular signal transduction and second messenger 
pathways. Most cytokines are growth and/or differentiation factors (Calleja-Agius & 
Brincat, 2008). 
Cytokines are also  hormones of the hematopoietic system which can affect the biologic 
behaviors of hematopoietic cells and processes, such as inflammation, wound healing 
and septic shock (Chau, Markley, Juang, & Tsen, 2016). They are also involved in 
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immunological, inflammatory and infectious diseases (Rasti, Z., Nasiri, M., & Kohan, 
L. 2016). 
Cytokines include chemokines (direct immune cells via chemotaxis to sites of 
inflammation), interferons (mediate cellular responses predominately to viral 
infections), interleukins (promote cell proliferation, maturation, migration, 
differentiation, and activation) or colony-stimulating factors (stimulate proliferation and 
differentiation of other target cells) (Chau et al., 2016). 
1.3.2 The pro-inflammatory and anti-inflammatory cytokines in 
recurrent miscarriage: 
Some women with idiopathic RM have increased production of pro-inflammatory 
cytokines such as tumour necrosis factor- (TNF-α) and interferon-γ (IFN-γ_) and 
decreased levels of anti-inflammatory cytokines such as interleukin-10 (IL-10) by 
peripheral blood mononuclear cells. Genetic polymorphisms associated with high and 
low production of a number of cytokines, including TNF-α, IFN-γ, and IL-10 have been 
found (Babbage et al., 2001). 
Although the mechanism of pro-inflammatory polarization is unknown, it may affect 
embryo implantation through a number of mechanisms. Excess pro-inflammatory 
cytokine (especially IFN-γ) could activate macrophage and induce its differentiation, 
which may express nitric oxide synthase (iNOS) and mediate directly the damage to 
trophoblasts. It was reported that both extravillous trophoblast proliferation and 
invasion were inhibited in vitro by the combined pro-inflammatory cytokines. 
For these reasons, the dominance of pro-inflammatory cytokines was probably one of 
the important factors affecting embryo implantation (Liang et al., 2015) (Fig 1.2). 
Failure to enable the shifting from a pro-inflammatory (Th1) to an anti-inflammatory 
(Th2) pattern, as evidenced by a persisting or dominant Th1 immune response, is 
associated with complications such as multiple implantation failures, RM, pre-
eclampsia, preterm delivery, and intra-uterine growth restriction  (Y. K. Choi & Kwak‐
Kim, 2008).  
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Figure 1.2: Cytokine balance during pregnancy. The pro-inflammatory Th1 response is 
important for maternal host defences whereas the Th2 reaction is important for inducing 
fetal immune tolerance. Imbalance of the immune responses may lead to adverse 
pregnancy outcomes such as gestational diabetes, preeclampsia, recurrent pregnancy 
loss, preterm labor and development of labor epidural-associated fever (Chau et al., 
2016) 
 
1.4 Medications that can be effective to prevent recurrent miscarriage 
Many Progesterone containing drugs are now available for treating women with RM. 
These medications reduce the chances of spontaneous miscarriage in women with 
unexplained RM improving the pregnancy outcome. Progesterone may promote the 
development of a cytokine microenvironment supporting pregnancy maintenance. It 
increases the expression of Th2-type cell responses and leukemia inhibitory factor. Thus 
the elevated concentrations of progesterone characteristic of early pregnancy may 
promote an immune environment sustaining pregnancy maintenance (Haas & Ramsey, 
2013). 
 
Progesterone-induced blocking factor (PIBF) prevents inflammatory and thrombotic 
reactions toward the fetus. PIBF, a protein synthesized by activated lymphocytes in the 
presence of progesterone, promotes this shift toward Th2 cytokines (Kumar et al., 
2014). One report from Egypt proved that progesterone have a great effect in reducing 
the risk of miscarriage if administered in the luteal phase of the cycle, before 
confirmation of pregnancy in women with history of unexplained RM (Ismail, Abbas, 
Ali, & Amin, 2018). In contrast other studies have proved that there was no evidence 
9 
 
that first-trimester progesterone therapy improves outcomes in women with a history of 
unexplained RM (Coomarasamy et al., 2016). 
 
1.5 Cytokine gene polymorphisms: 
Certain cytokine gene polymorphisms  in the promoter regions, exons or introns 
influence the level of cytokine secretion, (Y. K. Choi & Kwak‐Kim, 2008) 
There are now many well documented instances where nucleotide polymorphisms occur 
within the regulatory region of cytokine genes, some of these are associated with an 
altered rate of gene expression (Unfried et al., 2003). Many studies have shown that 
polymorphism of cytokine genes is associated with susceptibility to certain 
inflammatory and infectious disease (Y. K. Choi & Kwak‐Kim, 2008).  
Genotype and allele frequencies of cytokine polymorphisms show significant 
differences between different populations. Allele frequency variation was such that, 
within each cytokine, there was a tendency for at least one population to present itself as 
_different_ from the other groups: for example the Caucasian Northern Ireland group 
with a lower IL-6 -174G (high) allele frequency, relative to the other populations, and 
the complete absence of genotype IL-6 -174 CC (low) in the African group. Also those 
of Asian lineage exhibited an increase in IFN-y genotype + 874 A/A (L) that resulted in 
low expression as compared with whites. These differences show that the heredity of 
certain cytokine gene polymorphisms is strongly associated with ethnicity. It will be 
necessary to evaluate global frequencies for the variant alleles that may cause cytokine 
dysfunction and establish a data bank of information for future disease studies 
(Prigoshin, Tambutti, Larriba, Gogorza, & Testa, 2004) .  
Research efforts have focused on single nucleotide polymorphisms (SNP) in cytokine 
genes, and various SNPs have been reported to be related with infectious and 
inflammatory conditions, including the risk of pre-labour rupture of the amniotic 
membranes and preterm labor (Alkhuriji et al., 2013). 
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1.6 Interleukin-10 gene and idiopathic recurrent miscarriage: 
IL-10 is defined as a pleiotropic cytokine, is produced by activated Th2 cells, B cells, 
monocytes and macrophages. IL-10 is the most potent immunosuppressive and anti-
inflammatory molecule, one of anti- inflammatory cytokines that appear to protect 
against inflammation that leads to pregnancy loss (Alkhuriji et al., 2013). 
IL-10 gene is located on human chromosome 1 (1q31-q32) and plays an important role 
in the Th2 dependent immune responses. The processes including antigen presentation, 
T-cell proliferation, and selectively Th1-mediated cellular responses can be interfered 
by IL-10 through down-regulating the chemokines and pro-inflammatory cytokines, 
especially tumor necrosis factor-α and interferon-γ. 
Many single-nucleotide polymorphisms (SNPs) were reported in the proximal (at 
position -1082A/G, -819C/T and -592C/A) and distal regions of this gene and were 
reportedly associated in IL-10 transcription rate, thereby directly affecting its 
production level (Alkhuriji et al., 2013). 
 
Mutations in IL-10 have been detected at several loci, and the association between IL-
10 SNPs and disease risk has been heavily studied, Numerous molecular 
epidemiological studies have investigated the association betweenIL-10 gene 
polymorphisms and several types of cancer risk. One study published in 2006, 
explained the negative association between three IL-10 promoter polymorphisms and 
the risk of nasopharyngeal cancer in Italian populations (Niu et al., 2015). 
IL-10 (increase during labour), IL-10 and IL-4, named as protective agents during 
pregnancy, show a constant presence at the first two trimesters with IL-10 showing a 
peak of production during labour. This cytokine shows a minimal presence in the serum 
of pregnant or non-pregnant women at levels ranging from 0.14 to 0.88 ng/ml, implying 
a possible maintenance role during the gestation period (Vassiliadis, Ranella, 
Papadimitriou, Makrygiannakis, & Athanassakis, 1998). 
Many evidences suggests that IL-10 is elevated in some reproductive pathologies. IL-10 
levels have been shown to be significantly increased in amniotic fluid of small-
forgestational- age pregnancies as well as in severe pre-eclampsia (Y. K. Choi & Kwak‐
Kim, 2008). Q. Liu et al revealed that individuals carrying the CC genotype of IL-10 -
819T/C were associated with an increased risk of preeclampsia compared to the TT 
genotype  (Q. Liu et al., 2015) 
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During pregnancy, IL-10 is produced locally in the fetoplacental unit by 
cytotrophoblasts, and it up regulates the human leukocyte antigen (HLA)-G expression 
of cytotrophoblasts at the feto-maternal barrier. 
IL-10 gene polymorphism screening might have some relevance in RM patients. It was 
suggested that increased IL-10 expression was associated with successful pregnancy, 
whereas low levels were linked to recurrent fetal loss (Karhukorpi, Laitinen, Karttunen, 
& Tiilikainen, 2001). Previous in vitro studies showed that the GCC haplotype was 
related to increase IL-10 production, whereas the ATA haplotype was correlated with 
low levels of IL-10 production (Su et al., 2016) 
 
In humans, IL-10 production varies according to the presence of a specific allele at 
the1082 position where G⁄G variation determines a high cytokine production phenotype. 
Lin et al. concluded that the IL-10 592 AA genotype is correlated with a decreased risk 
of acute graft versus host disease; thus, the AA genotype may be associated with higher 
IL-10 production. Also, Temple et al. found that 819T and 592A alleles may increase 
stimulated transcriptional activity by influencing transcription factor binding. 
Furthermore, Hoffmann et al. indicated that the GCC haplotype (1082 ⁄819 ⁄592) is 
associated with decreased IL-10 production (Y. K. Choi & Kwak‐Kim, 2008). 
Results of a study conducted in Iran demonstrated an association for IL-10 gene 
polymorphisms including IL-10-592 A/C (rs1800872) and IL-10-819 C/T (rs1800871) 
But not IL-10-1082 A/G (rs1800896) promoter polymorphisms in idiopathic RM. Lack 
of any association between IL-10-1082 A/G polymorphism and RM was consistent with 
previous studies (Bahadori et al., 2014). In the same context, a study in Finland suggests 
that the IL-10 -1082 (G/A) polymorphism is not a major genetic regulator in RM 
(Karhukorpi et al., 2001). 
Kamali-Sarvestani et al. reported a significant association between the presence of IL-
10-1082 A/G polymorphism and the occurrence of RM in Iranian women (63% in 
women with RM and 46% in controls) (Kamali-Sarvestani, Zolghadri, Gharesi-Fard, & 
Sarvari, 2005). Zammiti et al. demonstrated an association between IL-10-592C/A and -
819C/T promoter polymorphisms among Tunisian RM patients (Zammiti et al., 2006). 
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A study in Romanian population demonstrated a role for -819 C/T but not -592 C/A 
IL10, -1082 A/G IL10polymorphisms in idiopathic recurrent miscarriage (Bohiltea & 
Radoi, 2014a). 
 
Other studies have shown that genotype and allele frequencies do not show any 
significant association between the unexplained RM patients and controls, and hence 
cannot be considered as a clinically important polymorphism linked to unexplained RM 
(Babbage et al., 2001), (Prigoshin et al., 2004) among Argentinian women, (Alkhuriji et 
al., 2013) among Saudi women, (ALHindi & Sharif) among Palestinian women in Gaza 
Strip, and (Kaur & Kaur, 2011) among Indian women. All of these studies demonstrated 
that there is not any association between RM patients and controls concerning the IL-10 
gene polymorphisms. 
Many case–control studies analyzed the relationship between the IL-10 promoter 
haplotypes (GCC, ACC, and ATA) and RM. The pooling results demonstrated no 
significant associations between the three haplotypes and RM risk based on the random-
effects model. The result indicated that the ATA haplotype was associated with 
increased RM risk (Su et al., 2016). This meta-analysis suggested that both rs1800896 
and rs1800871 polymorphisms have a positive relationship with RM, and women with 
A and C alleles for the rs1800896 and rs1800871 polymorphisms, respectively, could 
have effects on preventing RM. On the other hand, no sufficient evidence was found to 
detect the association between rs1800872 polymorphism and RM either in the overall or 
in the subgroup (Su et al., 2016). 
 
Discrepancy between results of genetic association studies like those encountered here 
could be due to many reasons including population genetic variation (background) 
unrelated to the investigated alleles, presence of nucleotide polymorphism somewhere 
else in the examined gene e.g., in the coding or intronic regions, epigenetic alterations 
and linkage disequilibrium to other sequence variants in the vicinity of the studied loci 
(Kaur & Kaur, 2011) 
 
Collectively, these reports highlight the need to analyze the association between IL-10 
gene polymorphisms and RM in different geographic regions and ethnic groups. 
 
13 
 
1.7 Interleukin-6 gene and idiopathic recurrent miscarriage: 
Interleukin-6 is a pleiotropic cytokine produced by a different cell types, including 
lymphocytes, monocytes and endothelial cells (Ma et al., 2012). 
IL-6, contributed in the inflammatory response and in the modulation of immune 
responses including B cell and T cell differentiation, functions as both a pro- and anti-
inflammatory cytokine (Lee, Choi, & Ji, 2015) 
Secretion of IL-6 leads to a stimulation of the hypothalamic, pituitary, adrenal axis 
during inflammatory processes, promotes osteoclastogenesis and participates in the 
development of osteoporosis associated with estrogen withdrawal. IL-6 is not 
constitutively expressed, but is highly inducible and produced in response to a number 
of inflammatory stimuli. Animal studies found that an increase in lL-6 concentrations 
precedes uterine contractions, suggesting that lL-6 plays a role in the physiological 
mechanisms involved in the propagation of labour. In human studies, IL-6 production 
has been described in the decidua during early pregnancy. Also, IL-6 has been shown to 
induce the release of hCG from trophoblasts, leading to a subsequent cascade of 
progesterone production, release of Th2 cytokines, and suppression of TH1 cytokines 
(Unfried et al., 2003)  
The IL-6 gene is located on chromosome 7p21, and of the several known 
polymorphisms in its promoter region, −174 G/C (rs1800795) and −634 G/C 
(rs1800796) have been the most frequently studied in RM. These two polymorphisms 
known to influence IL-6 expression, they are functionally significant and are known to 
display weak linkage disequilibrium (Lee et al., 2015).  
IL-6 levels in maternal serum, amniotic fluid, vaginal fluid, and placenta1have been 
found to increase during the process of normal labor compared with the non-labor state 
(Y. K. Choi & Kwak‐Kim, 2008). In other words, It was suggested that increased IL-6 
expression was associated with successful pregnancy, and increase significantly at the 
time of delivery, whereas low levels were linked with recurrent foetal loss. 
Additionally, decreased expression of IL-6 mRNA was demonstrated in the mid-
secretory phase of the menstrual cycle associated with habitual abortion (Ma et al., 
2012). 
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This is compatible with an anti-inflammatory role for IL-6 in pregnancy. On the other 
hand, elevated levels of IL-6 and pro-inflammatory cytokines, e.g. IL-1, TNF-a, and IL-
8 in the placenta, amniotic cells, and deciduas have been demonstrated in pregnancies 
complicated by preterm premature rupture of the membranes (pPROM), intrauterine 
infection and prematurity (Y. K. Choi & Kwak‐Kim, 2008) 
This cytokine is regulated principally at the transcriptional level by regulatory elements 
in its 5 flanking region, within which, the −174 G/C polymorphism acts as an important 
regulator of transcription (Lee et al., 2015) 
The first report on an IL-6 polymorphism in RM was in 2003 by Unfried, suggested that 
the IL-6 polymorphism  was not associated with RM and alterations in IL-6 serum 
levels in a Middle-European Caucasian population (Unfried et al., 2003). 
The other study has investigated the relationships between RM and single nucleotide 
polymorphisms at -634C/G in the promoter region of the IL-6 gene in the Japanese 
population. The results have shown a significant difference in the -634C/G genotype 
frequency (CC versus CG⁄GG) between women with RM and controls. The risk of RM 
was lower in the carriers of the G allele than in women with the wild type (CC) (Y. K. 
Choi & Kwak‐Kim, 2008). 
 
A study of IL-6 polymorphism 634C ⁄ G with RM in Chinese Han population showed an 
association between -634C ⁄G polymorphism and RM. This study demonstrated that RM 
risk in carriers of the G allele and the GG genotype was lower than that in women with 
the wild-type (Ma et al., 2012), this findings are entirely consistent with the previously 
published data by (Saijo et al., 2004) who suggested Japanese women carrying the-
634G allele of IL-6 gene had a decreased risk of RM. 
Kitamura et al. (2002) has indicated the presence of the -634G allele is associated with 
an elevated production and secretion of IL-6 protein by PBMC in vitro (Ma et al., 
2012). Demirturk et al. reported that the -174G/C genotypic and -174C allelic frequency 
of IL-6 was higher in RM Turkish patients than healthy controls, emphasizing the 
significant association of this SNP with RM in Turkish women. (Demirturk et al., 
2013). On the other hand, a study in Suadi females population, demonstrated that the 
IL-6 (-634C/G) polymorphism was not associated with recurrent miscarriage (Alkhuriji 
et al., 2013). 
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Furthermore, two studies in 2014 on IL-6 -174G/C, from Romanian (Bohiltea & Radoi, 
2014a), and Iranian women with RM (Bahadori et al., 2014), showed that there is  no 
statistically significant differences in the frequencies of IL-6 (-174 C/G) polymorphisms 
between RM women and controls. 
Results of a meta analysis study in 2015 showed that IL-6 −174 G/C and −634 G/C 
variants are associated with susceptibility to RM in non Caucasian and Asian 
populations, and a negative association was detected between the GG+GC genotypes of 
these polymorphisms and this disease (Lee et al., 2015) 
Based on the anti-inflammatory role of the IL- 6 in reproduction and due to lower IL-6 
expression, the polymorphic GG genotype might be observed in the women with RM. 
This assumption was confirmed by the results of a study carried out in Iran showing the 
higher frequency of GG+GC vs. CC genotypes among patients in comparison to control 
group. These results are inconsistent with data published from the Japanese experiment, 
as they introduce the G allele as a protective factor against recurrent pregnancy loss 
(Rasti, Nasiri, & Kohan, 2016). 
Several studies have shown the correlation of IL-6 with some diseases. A study by 
Brosseron et al. showed that there was increase of IL-6 plasma levels in patients with 
severe Alzheimer’s disease (AD)  compared with patients having less severe disease or 
healthy controls (Brosseron, Krauthausen, Kummer, & Heneka, 2014). This could be 
interpreted in the way that peripheral levels of IL-6 slightly increase over the time 
course of AD (Kalman et al., 1997). 
An individual's IL-6 genotype may be relevant to other conditions, such as juvenile 
systemic onset arthritis, development of Kaposi sarcoma and atherosclerosis. These 
clinical data suggest that carriage of the mutated IL-6 allele C confers protection against 
the development and course of inflammatory diseases (Unfried et al., 2003) 
 
1.8 Interleukin-17 gene and idiopathic recurrent miscarriage: 
The gene encoding IL-17 was discovered in 1993 in a rodent T cell library by 
subtractive hybridization (Gaffen, 2008) 
IL-17 (also known as IL-17A) is most homologous to IL-17F (~60%), and the genes 
encoding them are proximally located on chromosome 6. IL-17 and IL-17F exist as 
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homodimers (Gaffen, 2008). These two cytokines show high protein sequence 
similarity, bind to the same receptor and display similar biological activities. Binding 
IL-17 to its receptor initiates signalling pathways which induce the production of pro-
inflammatory cytokines and chemokines and induce the recruitment of neutrophils 
(Zidan et al., 2015).  In human recurrent pregnancy loss, excessive TH17 cells numbers 
and high levels of IL-17, IL-6 and IL-1beta have been identified, indicating that 
uncontrolled TH17 cells may emerge as an important mediator  (Fu et al., 2014). These 
cells are actively involved in the pro-inflammatory immune responses at the maternal-
fetal junction at the time of implantation which could subsequently lead to the 
development of RM (Zidan et al., 2015) 
The shift in the balance between the regulatory subpopulations of IL-17 producing 
lymphocytes (Th17)/T-regulatory lymphocytes (Tregs) towards Tregs exhibiting 
immunosuppressive activity could be important to maintain the immunological 
tolerance during pregnancy and explained the high IL-17 level in RPL (Heikkinen, 
Möttönen, Alanen, & Lassila, 2004) 
 
Few studies have examined the association of IL-17 A, IL-17 F, gene polymorphisms 
and their levels with RM. Bahadori et al did not find statistically significant association 
between IL-17 gene polymorphisms and the incidence of recurrent pregnancy loss. 
Chen et al. reported that IL-17 levels were not significantly different between RM 
women and normal fertile women (Zidan et al., 2015) 
 
Th17 are a novel subset of CD4+ T cells, which can be effective on tolerance during 
pregnancy. The proportion of IL-17 lymphocytes in the decidua is significantly higher 
than that in the peripheral blood in 1st trimester pregnant women (Fu et al., 2014).  
Some reports showed that allele A of IL-17A (rs2275913) presented with high serum 
levels of IL-17, and the expression and/or activity of IL-17 might be suppressed in IL-
17 F (rs763780) C allele carriers. 
A study by Saifi et al. reported significantly higher expression of IL- 17 in the 
unexplained RPL group compared to the normal non-pregnant group. Another study 
done by Wang et al. examined IL-17 cells and detected their prevalence increase in the 
peripheral blood and the decidua in unexplained recurrent pregnancy loss women 
(Zidan et al., 2015) 
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A study carried out in India showed that the proportions of Th17 cells and IL-17A 
concentration in peripheral blood in patients with RM were significantly higher than 
those in non-pregnant women and normal pregnant women, and  Treg frequencies were 
significantly lower in patients with RM than in normal  pregnant patients which 
conforms to the results demonstrated by Yang et al (Y. S. Liu et al., 2011).  
 
Najafi et al. found that IL-17 F (rs763780) TT genotype might be associated with a high 
risk of RM in Iranian women. On the other hand, no association found between of IL-
17A(rs2275913) polymorphism and the risk of RM (Najafi, Hadinedoushan, Eslami, & 
Aflatoonian, 2014) 
Zidan et al. suggested that there was association between IL-17 F (rs763780) 
polymorphism with decreased risk of RM in Egyptian females, but IL-17 A (rs2275913) 
SNP was associated with an increased risk of RM. Their results also demonstrated that 
the IL-17  levels was elevated in the women with RM in comparison to control group 
(Zidan et al., 2015). 
Wang et al. Studied IL-7A and IL-7F polymorphisms in Chinese Han women with 
breast cancer. they found an association between the SNPs in IL-17A but not IL-17F 
and breast cancer risk. 
Quan et al. demonstrated that there was a significant correlation between IL-17A 
rs2275913 and the risk for developing cervical cancer but no relation between IL-17F 
rs763780 gene polymorphism and cervical cancer was observed. Hayashi et al. 
investigated the association between gastro-duodenal disease and polymorphisms of 
rs763780 and rs2275913 in Japanese population. Their results indicated that rs2275913 
influences the susceptibility to gastro-duodenal ulcer. A study on Polish patients with 
rheumatoid arthritis showed that this SNP might be associated with increased disease 
activity in rheumatoid arthritis patients. Moreover, Epinoza et al. have reported an 
association between rs2275913 genotype in the recipient side with the development of 
acute graft versus-host disease following bone marrow transplants (Najafi et al., 2014) 
Since IL-17 has potent pathogenic properties, on the other hand, there are some 
mechanisms contribute to decrease its production or function. Both Th1 and Th2 
cytokines as IL-27 and IL-2 suppress the activity and Th17 development. Th17 cells 
produce IL-10, which reduces their pro-inflammatory function (Gaffen, 2008). 
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Chapter Two 
Materials and Methods 
2.1 Study population:  
A total of 107 convenient blood samples were collected from Palestinian women. Fifty 
five women aged 20-47 (mean 31.5 years) with a history of at least two miscarriages 
referred to the case group. The control group included fifty two healthy women, aged 
20-44 (mean 32.7 years) with at least two normal pregnancies and no pregnancy 
complications such as miscarriages, still births, pre-term babies, and preeclampsia. 
All the samples were collected from patient and healthy women during period between 
January 2017 and February 2018 from Palestine Medical Complex, Palestine Red 
Crescent Sociaty, Al Hiba IVF Center, Dr Omar Faisal Amr Medical Specialist Center, 
and Zughayer Medical Centers. Study patients were from different districts in the West 
Bank. 
 
2.2 Study Questionnaire: 
Interviews-based questionnaires were constructed for this study which aimed to collect 
general demographic and health status, patients files were reviewed also to collect 
medical data. Questionnaires were distributed and completed from all patients and 
healthy women. A copy of the study questionnaire is shown in Appendix C. 
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2.3 Assessment criteria: 
Exclusion criteria included anatomical abnormalities, previously known systemic 
disease, endocrine disorders, previous venous or arterial thrombosis or a family history 
of thromboembolism. Chromosomal abnormalities were ruled out (karyotype) before 
inclusion in the study. As infection was linked with recurrent spontaneous abortion 
(RSA), all subjects included were confirmed to be negative for the TORCH agents 
Toxoplasma gondii, rubella, cytomegalovirus (CMV), herpes simplex viruses (HSV-1 
and HSV-2), Varicella zoster virus (VZV) and human immunodeficiency virus (HIV-1 
and HIV-2). 
Inclusion criteria included women aged 20-47, divided into two groups: the control 
group, of healthy women with at least two normal pregnancies and no pregnancy 
complications such as miscarriages, still births, pre-term babies, and preeclampsia, and 
the case group included women with a history of at least two miscarriages without 
known medical causes. 
2.4 Ethical considerations: 
All subjects who agreed to participate in the study were briefed about the study aims 
and asked to sign informed consent. The principles of Helsinki declaration for scientific 
research were applied. 
2.5 Sample Collection and Preparation: 
Five ml of peripheral blood samples were collected under sterile conditions into tubes 
containing EDTA. Blood samples (5 ml from each sample) were centrifuged at 2000 
rpm for 15 minutes. From each sample 200 μl  buffy coat (the white interface between 
the plasma and the red blood cells) was transferred to 1.5 ml micro-tube to be used for 
preparation of genomic DNA. 
 
2.5.1 DNA Extraction: 
Genomic DNA was prepared from buffy coat using the DNA extraction kit ( QIAamp 
DNA Blood, Germany) according to the manufacture instructions. Briefly, a 200 μl of 
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red cell Lysis solution buffer and 20 μl of Proteinase K, were added to the tube with 
200μl buffy coat. The tube was vortexed vigorously, incubated at 56°C for 10 minutes. 
To remove the insoluble particles, 200 μl absolute ethanol was added then all the 
amount was transferred into spin column (filter tube), centrifuged for 1 min at 8000×g. 
For washing, 500 μl of first washing buffer was added and centrifuged for 1 min at 
8000×g, then 500 μl of second washing buffer was added and centrifuged for 4 minutes 
at 14000×g. Finally, spin column was transferred into a new 1.5 ml micro-tube,150 μl of 
elution buffer was added and centrifuged for 1 min at 8000×g. The eluted DNA was 
kept at -20C until use. 
 
2.5.2 DNA Quantification: 
DNA concentration was measured spectrophotometrically using (Nanodrop 2000c; 
Thermoscientific). Elution buffer TE (Tris-EDTA buffer) was used as a blank, spectral 
measurement at 230nm, 260nm, and 280nm were also done and the ratios (260/280 nm 
and 260/230 nm) were calculated to assess the purity of DNA samples. DNA 
concentration was adjusted to (50-150 ng/μL) in each 25 μl PCR reaction. Concentrated 
DNA samples were diluted with ultra distilled water. In the case of low concentration of 
DNA in samples, the volume of DNA was increased. Samples with good purity and 
A260/A280 ratio about (1.6 to 2) were used in the PCR. 
2.6 PCR Amplification: 
2.6.1 Primers 
The primers (forward and reverse) were selected on the basis on their design by 
previously published studies, (Table 2.1), primers were checked by Primer BLAST  in 
Pubmed, NCBI, software( http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
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Table 2.1: The main properties of the primers used in this study. 
Gene 
SNP 
Primer Primer sequence Primer 
size bp 
Amplicon 
size bp 
Annealing 
Temp °C 
Ref 
IL-17A (F) 5’- TCT CCA TCT CCA 
TCA CCT TTG -3’ 
21 
815 bp 57 
(Najafi 
et al., 
2014) 
(R) 5’- GTC CAA ATC AGC 
AAG AGC ATC -3’ 
21 
IL-17F (F) 5’-CAC TGG TGC TCT 
GAT GAG GA- 3’ 
20 
635 bp 54 
(R) 5’- CATTGT GCT TTG GCT 
TGC T- 3’. 
19 
IL-10 
AC 
(F) 5'-GGTGAGCACTACCTG 
AC TAGC -3' 
21 
412 bp 61 
(Bahad
ori et 
al., 
2014) 
(R) 5'-CCTAGGTCACAGTGAC 
GTGG -3' 
20 
IL-10 
CT 
(F) 5'- TCATTCTATGTGCTGG 
AGATG -3' 
21 
209 bp 57 
(R) 5'- TGGGGGAAGTGGGTA 
AGAGT -3' 
20 
IL-6 
174 
(F) 5'-TGACTTCAGCTTTACT 
CTTTGT -3' 
22 
198 bp 57 
(R) 5'- CTGATTGGAAACCTT 
ATTAAG -3' 
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2.6.2 The PCR Protocol: 
Genomic DNA was amplified by polymerase chain reaction (PCR) using IL-10 ( -819 
C/T and -592 A/C), IL-6(-174 C/G) and (IL-17A, IL-17F) specific primers (Table 1). 
Each PCR reaction with a final volume of 25 μl contained 5 μl of DNA, 7 μl distilled 
water,1.25 μl of each of the reverse and forward primers, and 12.5 μl  PCR master mix 
(Ready Mix PCR Master Mix of Thermo scientific, Cat. No. AB-0575/Dc/LD/A) for 
IL-10, IL-6, and IL-17F genes.  While Green Master Mix (green GoTaq® reaction 
buffer, Promega) was used for IL-17 A gene.  The reaction was carried out in PCR tube 
(0.2 ml Axygen INC, USA) using GeneAmp PCR System 9700. Gradient PCR was run 
first to find the optimum annealing temperature for each primer). Thermal cycling was 
performed as shown in Table 2.2. Nuclease-free water was used as negative control in 
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each run.  The reaction was then stored at 4ºC and either frozen at -20ºC or directly 
separated. 
Table 2.2. Thermal cycling programs for amplification of IL-10, IL-17, and IL-6 
PCR program 
IL-6, IL-17A, IL-
10C/T amplification 
IL-17F 
amplification 
IL-10A/C 
amplification 
Temp Time Temp Time Temp Time 
Initial denaturation 94 ° C 5 min 94 ° C 5 min 95 ° C 5 min 
Denaturation 94 ° C 1 min 94 ° C 1 min 94 ° C 1 min 
Annealing 57 ° C 1 min 53 ° C 1 min 63 ° C 30 sec 
Extension 72 ° C 1 min 72 ° C 1 min 72 ° C 1 min 
Final extension 72 ° C 5 min 72 ° C 5 min 72 ° C 6 min 
No. of cycles 32  35  35  
 
2.7 Gel electrophoresis: 
To detect the amplified gene product of the PCR reactions, agarose gel electrophoresis 
was used to separate the PCR product.  2 % agarose (STANDARD AGAROSE) was 
prepared by dissolving 2g of agarose in 100 ml solution of 1x Tris-acetate EDTA buffer 
( TAE) (40 Mm of Tris acetate pH 8; and 1 mM EDTA).  The agarose was boiled until 
it was well dissolved, and then 4μl of 10 mg/ml (0.4μg/ml) of ethidium bromide was 
added for DNA staining. When agarose suspension cooled down to 40°C, carefully 
mixed, poured into agarose gel casting system (BioRad, UK  or Cleaver, U.S.A) and a 
desired comb was inserted. Five µl of the PCR product was added directly into the gel 
well along with the DNA size control; 5 µl from 100 bp marker (gene ruler express 
DNA ladder, (GeneDirex, cat number. DM001-R500) was added to detremine the 
correct band size.   Finally, the migrated bands in the agarose gel (100 voltage for 
40min) were visualized under UV light, (VILBER LOURMAT). 
 
2.8 Restriction fragment length polymorphism (RFLP): 
All PCR products were used in the PCR-RFLP analysis. Genomic DNA that was 
amplified was subjected to RFLP analyses using the restriction enzymes used by others, 
(Najafi et al., 2014) and (Bahadori et al., 2014).  
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A total of four restriction enzymes were used to digest the amplified products in order to 
screen for genetic differentiation: Rsa I, Mea III, EcoNl and NlaIII ( Thermo scientific, 
EU) enzymes were employed to determine the IL-10 (-592 A/C, -819 C/T), IL-17A, IL-
17F and IL-6 (-174 C/G) variants, respectively (Table 2.3). All restriction digestions 
followed the standard procedure provided by the manufacturer. 
To make a final solution of 32 μl for each samples, 10 μl of PCR reaction mixture, 18 μl 
nuclease-free water, 2 μl 10X enzyme buffer, and 2 μl of enzyme . The mixture in the 
tube was then incubated in a water bath for a specific period of time as shown in Table 
2.3. 
Table 2.3 Restriction enzymes used for cytokine genes polymorphisms. 
Polymorphisms Amplicon 
size (bp) 
Restriction 
Enzyme 
RFLP Size 
(bp) 
Temp Time 
IL-10 -592 A/C 412 bp Rsa I 236, 176 37 °C 1-16 hours 
IL-10 -819 C/T 209 bp Mae III, 125, 84 55 °C 1 hour 
IL-17 A 815 bp EcoNl 259, 270, 
286, 529 
37 °C 1-16 hours 
IL-17 F 635 bp NlaIII 124, 130, 
381, 511 
37 °C 1-16 hours 
IL-6 -174 C/G 198 bp NlaIII 140, 58 37 °C 1-16 hours 
 
Different concentrations of agarose gel were used in order to find an optimum gel 
concentration to visualise the digested fragments. The concentration of 3-3.5% was 
chosen to obtain a good separation of the bands. The gel was prepared and documented 
as mentioned above. The digested fragments were compared to a 50 bp, 100 bp DNA 
marker (5 μl) run on the same gel to establish the sizes of the bands cut for each sample. 
 
2.9 Bioinformatics, Blast, and getting the FASTA sequence from NCBI 
BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi ) was used to get the FASTA 
sequences for each interleukin, by accession number used by researchers and data bases 
to refer to specific SNP, all sequences were recognized by entering forward and reverse 
primers for different interleukins genotypes severally, see appendix A. NEBcutter 
software (http://nc2.neb.com/NEBcutter2/) was used to make virtual cut of sequences to 
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be sure of restriction site position and fragments length for all genotypes. See Appendix 
B 
 
2.10 Statistical analysis: 
Collected data were analyzed using the Epi Info version 7.2.2.2 and statistical package 
for the social sciences (SPSS) software version 22 for Microsoft windows. 
Genotype distributions of cytokine gene polymorphisms were compared between cases 
and controls by Chi-square test. Correlations between the polymorphisms were 
calculated by Spearman Coefficient correlation. Significance was set at P-value < 0.05. 
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Chapter Three 
Results 
A total of 107 individuals (55 patients and 52 healthy volunteers) were included in this 
study, questionnaires were completed from all patients and healthy volunteers, 
(Appendix C). Samples were recruited from different regions of Palestine: 33 samples 
were obtained from Ramallah, 30 from Al-Khalil, 24 from Jerusalem, 7 from 
Bethlehem, 6 from Nablus, 5 from Tulkarem and 2 from Jericho. Data about age, 
height, weight, health status, and smoking were reported from case and control groups. 
Tight criteria have been put to include or exclude study groups. The primary data which 
were included in the questionnaire were summarized in Table 3.1 
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Table 3.1 Clinical data and characteristics of the studied subjects 
 Healthy 
controls (n=52) 
RM patients 
(n=55) 
Exact 95% LCL Exact 95% 
UCL 
Age (years) Mean=33 Mean=31.8 21.44% 39.52% 
Height (cm) Mean=164 Mean=164.3 2.09% 11.81% 
Weight (kg) Mean=65.34 Mean=67.37 4.57% 16.52% 
smokers 8 5 6.63% 19.88% 
Negative smokers 29 27 43.34% 63.13% 
Number of live births Mean=4.1 Mean=2.3   
Number of  
miscarriages 
0 Mean=3.8   
Age menses began Mean=12.5 Mean=13.1 16.14% 33.02% 
Regular menses 40 (76.9%) 38 (69%) 63.45% 81.04% 
* LCL: lower control limit 
* UCL: upper control limit 
* n: number 
As shown in table 3.1, no statically significant difference was found in the above 
variables (P>0.05) between the case vs. the control groups, excluding their rules as risk 
factor for recurrent miscarriage. 
A negative statistically significant difference was found between the two groups 
concerning the administration of oral contraceptive pills, P= 0.0013 (Table 3.2). This 
negative association could be attributed to the fact that contraceptive pills are 
principally composed of progesterone , which has an effective role in the next 
pregnancy.  
Table 3.2: The distribution of study population according to contraceptive pills taken 
contraceptive 
pills 
Frequency % 
Percent 
Exact 95% 
LCL 
Exact 95% 
UCL case control 
Yes 6 (10.9%) 20 (38.5%) 24.30% 16.53% 33.54% 
No 49 (89%) 32 (61.5%) 75.70% 66.46% 83.47% 
TOTAL 107 100.00%     
* LCL: lower control limit 
* UCL: upper control limit 
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3.1 Distribution of IL-17 F, IL-17 A, genotypes and alleles in the 
studied groups 
The undigested PCR product size was 815 bp for IL-17A SNP rs2275913. Restriction 
digestion for the GG genotype (homozygous wild type) generated 259, 270 and 286 bp 
fragments; whereas the AG genotype (heterozygous) generated 259, 270, 286 and 529 
bp and the AA genotype (homozygous mutant) produced 286 and 529 bp fragments. 
There was no significant difference in the frequency of the G allele between the control 
and case group, (20.1%, and 28%, respectively). Also the A allele frequencies of the 
control group vs. the case group were (79.8% and 72%, respectively). So the 
comparison between the population of the case and the control groups in the three 
genotypes of AA, AG and GG revealed no significant difference (P=0.1456) (Table 3.3) 
 
Table 3.3: The frequencies of IL-17 A, IL-17F, genotypes and alleles in RM and control group 
genotypes 
Healthy 
controls 
(N=52) (%) 
RM case 
(N=55) (%) 
Exact 
95% 
LCL 
Exact 
95% 
UCL 
P-value Chi-
square 
IL-17 A 
(rs2275913) 
GG  2 (3.8%) 5 (9%) 2.67% 13.02% 0.1456 3.8537 
AG 17 (32.7%) 21 (38.2%) 26.5% 45.35% 
AA 33 (63.5%) 29 (52.8%) 48.01% 67.42% 
G% 20.1% 28%     
A% 79.8% 72%     
IL-17 F 
(rs763780) 
TT 19 (36.5) 25 (45.5%) 31.7% 51.05% 0.4066 1.8 
CT 32 (61.5%) 30 (54.5%) 48.01% 67.42% 
CC 1 (2%) 0 (0%) 0.02% 5.1% 
T% 67.3% 72.7%     
C% 32.7% 27.3%     
* LCL: lower control limit 
* UCL: upper control limit 
 
For IL-17F, The undigested PCR product size was 635 bp for SNP rs763780 (Fig. 3.1). 
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Fig 3.1: Agarose gel electrophoresis showing PCR products for IL-17F. The undigested PCR product size 
is 635 bp, Lane 3 is negative control 
 
TT genotype (homozygous wild type) produced 124,130 and 381 bp fragments; the CT 
genotype (heterozygous) generated 124, 130, 381and 511 bp fragments and CC 
genotype (homozygous mutant) was characterized by 124 and 511 bp fragments (Fig. 
3.2). There was no significant difference in the frequency of the C allele, it was 32,7%  
in the control and 27.3% in the case group. The frequency of allele T was 67.3% in the 
control group, and 72.7% in the case group. 
The comparison between the population of the case and the control groups in the three 
genotypes of CC, CT and TT showed no significant difference (P=0.4066). 
 
 
 
 
Fig 3.2: Restriction fragment polymorphism (RFLP) analysis of IL-17 F product using NlaIII enzyme. 
The digested product was loaded on 3% agarose gel. Lanes 5 and 7 are negative controls, lane 1and 3 are 
TC genotype, lanes 2, 4, 6 and 8 are TT genotype.  
       1             2                  3            4                5                 6              7              8       lad 100bp 
100 bp 
500 bp 
Lad 100    1         2           3          4           5          6           7            8           9          10 
500 bp 
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3.2 Distribution of IL-6-174C/G, genotypes and alleles in the studied 
groups 
 
The undigested PCR product size was 198 bp for SNP rs 1800795 (Figure 3.3). 
Restriction digestion for the GG (homozygous mutant) genotype generated one band at 
198 bp, (Figure 3.4); whereas the CG genotype generated 198, 140 and 58 bp and CC 
(wild type) genotype produced two bands at 140 and 58 bp fragments. NlaIII digestion 
enzyme cut the normal genotype, (NlaIII/ it is a type of restriction enzyme that 
abolishes a restriction site),  this process was confirmed by retrieving the original 
sequences of the gene from BLAST/ FASTA website, see Appendix A, then inserting 
into NEBcutter which determines virtual restriction site position and fragments length. 
See Appendix B 
 
                 
 
  Fig 3.3: Agarose gel electrophoresis showing PCR product for SNP rs1800795. The undigested PCR 
product size is 198 bp, Lane 10 is negative control 
 
The frequency of the genotypes and allelic frequencies are presented in Table 3.4. No 
significant differences were found between the case patients and the control groups. The 
CC genotype ( homozygous wild type) was reported in one patient in the case group  
and was not reported in the control group. Our data show that there is no association 
between the presence of allele C in position -174 from the region of the IL6 gene 
promoter and recurrent pregnancy loss. 
 
 
 
 1          2           3          4          5          6          7           8           9          nc       lad 100 
200 bp 
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Table 3.4: The frequencies of IL- 6, genotypes and alleles in RM and control groups 
genotypes 
Healthy 
controls 
(N=52) (%) 
RM case 
(N=55) 
(%) 
Exact 
95% LCL 
Exact 
95% UCL 
P-value Chi-square 
IL-6 -174G/C 
(rs1800795) 
GG 33 (63.5%) 37 (67.3%) 60.28% 69.8% 
0.9939 
 
0.0122 
 
GC 19 (36.5%) 17 (30.9%) 29.8% 36% 
CC 0 (0%) 1 (1.8%) 0.05% 4.9% 
G% 81.7% 82.7%   
C% 18.3% 17.3% 
* LCL: lower control limit 
* UCL: upper control limit 
 
 
              
 
 
Fig. 3.4: Restriction fragment length polymorphism (RFLP) analysis of IL-6-174C/G product using  
NlaIII enzyme. The digested product was loaded on 3.5% agarose gel. Lanes 1, 2, and 6 are GG genotype, 
while lanes 3, 4, and 5 are CG genotype. M: marker, 100, 50 bp ladder  
 
3.3 Distribution of IL-10-592 A/C and IL-10 -819 C/T, genotypes and 
alleles in the studied groups 
The undigested PCR product size was 412 bp for IL-10 A/C, SNP rs1800872 (Fig. 3.5). 
Restriction digestion (RsaI enzyme), for the AA genotype (homozygous wild type) 
generated 236 and 176 bp fragments; whereas the AC genotype (heterozygous) 
generated 412, 236 and 176 bp and the indigestible fragment length 412 CC 
(homozygous mutant),(Fig. 3.6). The cutting here was in the normal genotype sequence, 
because RsaI is a type of restriction enzyme that abolishes a restriction site,  this process 
was confirmed by getting the original sequences of the gene from BLAST/ FASTA 
     1                2                   3                  4                 5                   6                 Lad 100       Lad50bp 
140 bp 
150 
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website, and compare it to SNP sequence, (Appendix A), then insert it into NEBcutter 
which determine restriction site position and fragments length. When the original 
sequence of IL-10 A/C was inserted to the NEBcutter website the cutting was 
performed with Rsa I enzyme generated two DNA fragments 236 and 176 bp, while it 
was uncut at the SNP site. 
 
 
Fig 3.5: Agarose gel electrophoresis showing PCR product for SNP rs1800872. The undigested PCR 
product size is 412 bp. 
There was no significant difference in the frequency of allele A, (with 33.66%, and 
35.45% in the control and case group respectively). Also the frequency of allele C was 
66.34% in the control group and 64.55% in the case group.  So the comparison between 
the population of the case and the control groups in the three genotypes of AA, AC and 
CC revealed no significant difference (p=0.9626) (Table 3.5). 
 
Table 3.5: The frequencies of IL-10 A/C, IL-10 C/T, genotypes and alleles in RM and control 
groups 
genotypes Healthy 
controls 
(N=52) (%) 
RM case 
(N=55) 
(%) 
Exact 
95% 
LCL 
Exact 
95% 
UCL 
P-value Chi-square 
IL-10 AC 
(rs1800872) 
CC 23 (44.2%) 23 (41.8%) 33.46% 52.92% 
0.9626 
 
0.0762 
 
AC 23 (44.2%) 25 (45.5%) 35.23% 54.78% 
AA 6 (11.6%) 7 (12.7%) 6.63% 19.88% 
C% 66.34% 64.55%   
A% 33.66% 35.45%   
IL-10 CT 
(rs1800871) 
TT 11 (21.2%) 8 (14.5%) 11.04% 26.33% 
0.0009 
 
14.054 
 
CT 41 (78.8%) 34 (61.8%) 60.48% 78.56% 
CC 0 (0%) 13 (23.7%) 6.63% 19.88% 
T% 60.58% 45.45%   
C% 39.42% 54.54%   
500
32 
 
 
 
 
 
Fig. 3.6: Restriction fragment length polymorphism (RFLP) analysis of IL-10-592 A/C product using 
RsaI  enzyme. The digested product was loaded on 3.% agarose gel. Lanes 6, 7, are AA genotype, (wild 
type allele) while lanes 3, 5, and 9 are AC genotype (heterozygous), the rest lanes are CC genotype. 
The undigested PCR product size was 209 bp for IL-10 C/T SNP rs1800871 (Fig. 3.7). 
Enzymatic digestion with Mae III generated 125 and 84 bp fragments for the CC 
genotype (homozygous mutant); whereas the CT genotype (heterozygous) generated 
209, 125 and 84 bp and the indigestible fragment length was 209bp TT (homozygous 
wild type),(Fig. 3.8). The digestion by Mae III enzyme was in the SNP site, because 
Mae III is atype of enzyme that creats a restriction site. 
 
Fig 3.7: Agarose gel electrophoresis showing undigested PCR product for IL-10 C/T SNP rs1800871 at 
size of 209 bp. 
The genotypes frequencies of polymorphism of rs1800871 in the case group were TT 
(14.5 %), CT (61.8 %) and CC (23.7 %). The frequencies were TT (21.2 %), CT (78.8 
%) and CC (0 %) in the control group.  
   1           2             3           4          lad 100    5          6           7           8           9         10        11 
100 bp 
200 bp 
236 bp 
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The frequency of allele C of SNP rs1800871 in the two groups was significantly 
different (P=0.0009). The frequency of mutant allele C was 54.54 % in the case group 
and 39.42 % in the control group. Besides, the frequency of allele T was 45.45 % in the 
case group and 60.58 % in the control group. The comparison between the case and the 
control group showed a significant difference in the three genotypes of TT, CT and CC 
(P=0.0009). The results are shown in Table 3.5. 
 
 
Fig 3.8. RFLP analysis of IL-10 -819 C/T polymorphism using Mae III enzyme on 2.5% 
agarose electrophoresis . The polymorphic region was amplified by PCR resulting in digestible 
fragment length 125 and 84 bp in lane 2, 3, 4, 5, 9, 10, 16 and 18 (CC mutant homozygote), 
indigestible fragment length 209 bp in lane 1, 8, and 14 (TT normal homozygote). Three 
fragments 209, 125, 84 bp (lane 6, 7, 11, 12, 13, 15,17 and 19) represent CT heterozygote. M: 
marker, 100 bp ladder, (all of these samples are from the case group). 
 
 
 
 
   1      2      3      4       5      6       7      8      9      10    11    12    13   14    15    16   17     18   19   lad 
209 bp 
500 
34 
 
  
 
Fig. 3.9: Distribution of IL-10 -819 C/T, genotypes and alleles in the studied groups 
 
Our results revealed a possible association of polymorphism -819 C/T and the increased 
frequency of recurrent abortions and the lack of association between polymorphisms 
IL10-592C/A, IL6-174G/C, IL-17 and the abortion disease in the studied group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frequency 
Genotype 
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Chapter Four 
 
Discussion 
 
Pregnancy depends on the induction of maternal tolerance to fetal tissues; decidual cells 
will inhibit maternal immunity during pregnancy. Natural killer cells migrate into the 
uterus during implantation coordinating the secretion of cytokines that help or limit 
trophoblast invasion (Bohiltea & Radoi, 2014b). The etiology of recurrent abortions is 
heterogeneous (infectious, genetic, anatomic, hormonal factors are involved), 
accentuated by the acquired or birth risk factors (Bohiltea & Radoi, 2014b). Recurrent 
miscarriageis mediated by complex immunologic factors. 
Cytokines are of vital importance in the regulation of cellular function (Su et al., 2016)  
Cytokines are secreted by the cells within the uterine lining and these cytokines 
stimulate the expression of adhesion systems that hold the embryo to the uterus. If the 
immune cells don’t send specific signals through secretion of convenient cytokines to 
the embryo or if these cells don’t respond to signals from the embryo, then adhesion and 
thus subsequent implantation will not occur (Kasap et al., 2015). Many studies are 
concerned in explaining the immunological and biological roles of cytokines during 
pregnancy, especially those in maternal peripheral blood and in uteroplacental tissues 
(Ozkan et al., 2015) 
 
Interleukins are a group of immunomodulatory proteins that mediate a variety of 
immune reactions in the body (M. Zhang et al., 2017). Variants of genes alter the 
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corresponding protein expression levels. Therefore, it was necessary to assess the global 
frequencies of the variant alleles of interleukins that might cause RM. 
 
To the best of our knowledges, no previous studies have been conducted in the West 
Bank to study the roles of cytokines polymorphisms and RM. This case control study 
included 107 random samples collected from Palestinian women from different cities in 
Palestine. In the current study we supposed a possible correlation between 
polymorphism IL-10-592 A/C (rs1800872), IL-10-819 C/T (rs1800871), IL-17A 
rs2275913, IL-17F rs763780 and IL-6 -174G/C SNP (rs1800795) and  recurrent 
abortions. Reactive criteria have been put to include or exclude blood samples, based on 
specific health conditions, interviews, questionnaires for patients and healthy women 
volunteer to participate in this study to exclude patients with other known reason for 
RM. (Appendix C). 
 
IL-6 takes part in trophoblast proliferation, differentiation and invasion and participates 
in follicle development and embryonic implantation. (Galazios et al., 2002) . The IL-6 
protein also plays a part in the initial spiral artery remodeling that requires vascular 
smooth muscle cell induction and morphological change. Reduced levels of IL-6 
decrease trophoblast invasion and spiral artery remodeling (Pitman, Innes, Robson, 
Bulmer, & Lash, 2013) 
IL-6, secreted by decidual cell populations, is a potent pro-angiogenic cytokine that 
stimulates the proliferation of endothelial cells in vitro and regulates the behavior of the 
female reproductive tract and gestational tissues (Pitman et al., 2013). Based on many 
evidences about the role of IL-6 in the immunology of pregnancy was based on the 
highest level of IL-6 mRNA in the implantation and menstruation period and the 
presence of its receptors on the endometrium and trophoblast (Nasiri & Rasti, 2016) 
During this study, we did not find any association between C/G -174 polymorphism in 
IL-6 gene and recurrent miscarriage. Whereas the IL-6 −174 C allele was rare in our 
results. Most of the patients (67.3%) and controls (63.5%) are homozygous to the 
mutant allele (GG). The heterozygous allele (CG) state occurs in (31%) of patients and 
(36.5%) of the controls, while the homo normal genotype (CC) occurs only in (1.8%) in 
patients and (0%) in controls. The frequencies of the genotypes and alleles do not show 
any significant difference between the unexplained RM patients and controls. 
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Our results are consistent with many previous reports (Bohiltea & Radoi, 2014b), 
another study showed that the frequency of allele C was 0.06% in the studied lot 
compared to 0.40-0.45 at the Caucasian population. Allele C has not been identified in 
position -174 in a study performed on 388 Japanese men and at only one person in a 
study performed on 259 Chinese men (Hayakawa, 2002), the IL-6 −174 C allele has not 
been observed in Japanese subjects (Saijo et al., 2004) and is known to be rare in 
Chinese and Korean populations (Lim et al., 2002), while this allele is common in 
Caucasians.  
While other observations proved that the normal homozygous allele (CC) is common in 
Iran and occurs approximately (42%) in both healthy and RM women, but the study did 
not find any association between IL-6−174 polymorphism and RM  (Bahadori et al., 
2014). Lee et al. showed that IL-6 −174G/C, polymorphism is associated with 
susceptibility to RM, particularly in non-Caucasians (Lee et al., 2015), which was in 
contrast with our results. In the same context, the results of a study conducted in 2003 
proved that the  C allele was found to be associated with significantly lower levels of 
plasma,IL-6, whereas  G allele was associated with higher IL-6 serum levels (Unfried et 
al., 2003). 
Nakashima et al. showed that IL-17-positive T cells accumulated in the deciduas of 
women with RPL (Nakashima et al., 2010).  Wang et al. found that the proportion of 
Th17 cells in the peripheral blood and the decidua of women with inevitable abortion 
were significantly higher than women with normal pregnancy (Wang et al., 2011). T 
helper (Th) 17 cells are a novel subset of T cells which secrete IL (Interleukin)-17. 
Th17 cells are known to be involved in the pathogenesis of autoimmune diseases, 
inflammation and immunological rejection of non-self tissue (Ivanov et al., 2006). 
Few studies have examined the association of IL-17 A, IL-17 F, polymorphisms and 
their levels with RPL; however, their data are controversial. In addition, only few 
studies have been conducted so far for finding out the effect of these polymorphisms on 
their cytokines levels in RM patients. Therefore, further studies in different populations 
are essentials. Our study to find relationship between IL-17A, IL-17F polymorphisms 
and idiopathic recurrent miscarriage, showed that, in the RM group, the genotypes 
frequencies of rs2275913 polymorphism were GG (9.0 %), AG (38 %), and AA (53 %) 
and in the control group, were GG (1.9 %), AG (34.6 %) and AA (63.5 %). 
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The genotypes frequencies of rs763780 polymorphism were TT (45.4 %), TC (54.6%) 
and CC (0 %) in the RM group; whereas the frequencies were TT (36.5 %), TC (61.6%) 
and CC (1.9 %) in the control group. 
 
Our results demonstrated that there was no significant difference between the genotypes 
in the two groups. Statistical analysis did not show any association between (IL-17A, 
nor IL-17F) polymorphisms and recurrent miscarriage, our results are consistent with a 
study by Bahadori et al. who did not find statistically significant association between 
IL-17 gene polymorphisms and the incidence of recurrent pregnancy loss (Bahadori et 
al., 2014). 
In contrast to our findings,  other reports have shown a significant association between 
IL-17 gene polymorphisms and risk of RM, a study conducted in Egypt found that IL-
17 F (rs763780) polymorphism was associated with a decreased risk of RM in Egyptian 
females, but they also found that IL-17 A (rs2275913)  SNP was associated with an 
increased risk of RM (Zidan et al., 2015). Another study indicated that IL-17F 
polymorphism,rs763780, might be associated with a high risk of RM in Iranian women, 
but there was not any association with IL-17A SNP (Najafi et al., 2014). 
 
IL-10, produced by cytotrophoblasts and decidual T cells, protect the fetal-placental 
interface by reducing the cytokine secretions of Th1 cells and macrophages (Fan et al., 
2011). 
There are 3 famous IL-10 SNPs  located in the promoter region (− 1082A > G 
(rs1800870), − 819T > C (rs1800871) and (− 592A > C (rs1800872)) which have been 
reported to regulate IL-10 transcription and expression (Kingo et al., 2005), thereby 
directly affecting IL-10 production levels (Alkhuriji et al., 2013). However the role of 
IL-10 in RM pathogenesis remains controversial (Bohiltea & Radoi, 2014b). 
In this study, our results showed that the IL- 10-592 A/C polymorphism in the IL10 
gene promoter is present in unexplained RM patients and controls, where most of the 
patients (45.5%) and controls (44.3%) are heterozygous for the genotype (AC). The 
homozygous mutant genotype state (CC) was reported in (41.8%) of patients and 
(44.2%) of the controls, while the normal genotype (AA) occurs in (12.7%) in patients 
and (11.5%) of controls. The genotype and allele frequencies in the above 
polymorphism showed no significant difference between the unexplained RM patients 
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and controls, thus cannot be considered as a clinically important polymorphism linked 
to unexplained RM. 
This study was in disagreement with previous studies which reported a significant 
association between the presence of polymorphism and the occurrence of RM in Iranian 
and Tunisian women (Bahadori et al., 2014), (Kamali-Sarvestani et al., 2005),  
(Zammiti et al., 2006).  
Statistical analysis of our results revealed that IL-10 -819 C/T polymorphism was 
associated with RM (p<0.05). In the RM group, the genotypes frequencies of 
(rs1800871) polymorphism were TT (14.5 %), CT (61.8 %), and CC (23.6 %) and in the 
control group, were TT (21.1 %), CT (78.9 %) and CC (0 %).  
This finding is in agreement with previous reports which demonstrated an association for IL-
10-819 C/T gene polymorphism in idiopathic RM (Su et al., 2016), (Bahadori et al., 2014), 
(Bohiltea & Radoi, 2014b).    
Other reports revealed no association between RM patients and controls concerning the 
IL-10 gene (Prigoshin et al., 2004) and (Kaur & Kaur, 2011) which were in contrast 
with our findings. 
These discrepancies may be explained by ethnic differences of the study groups as well 
as by number variations of the subjects that are included in the research. 
Through interviews with the women who suffered from idiopathic recurrent pregnancy 
losses, some of them got a successful pregnant when they take progesterone 
medications.  
Progesterone might play a significant role in establishing a convenient immune 
environment at early stages of pregnancy (B. C. Choi, Polgar, Xiao, & Hill, 2000).  
Therefore, using of progesterone in high-risk patients reduced the incidence of 
premature delivery and may help to establish a sufficient immune response in early 
pregnancy and prevent miscarriage (Kumar et al., 2014).  The progesterone deficiency 
has been related with insufficient endometrial maturation and inappropriate regulation 
of inflammatory cytokines. There was a significant progressive increase in the level of 
IL-10 through first, second and third trimester in the progesterone treatment in women 
with unexplained recurrent miscarriage (Ismail et al., 2018). 
No positive associations were found between risk of RM and smoking, negative 
smoking, and consumption of coffee. Our findings are in consistent with reports by (B. 
Y. Zhang et al., 2010), which did not find any relationship between smoking, alcohol 
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consumption, and coffee consumption and increased risk of RM. But this study found 
that the increased risk of RM was significant for participants with a BMI of 24.0 or 
greater and those with a family history of miscarriage, and that was contrary of our 
results.  
 
Conclusion 
Taking into account the results obtained in this study, as well as the results of previous 
studies we may conclude that there is not only one genetic factor, but possibly several 
that are involved in the abortion disease etiology, as idiopathic factors. If the 
relationship between genetic factors and the immune system disorders is cleared, 
genetic polymorphisms as the one that is studied may represent markers for selecting 
the therapeutic options and for counseling patients with recurrent spontaneous 
abortions. The recurrent spontaneous abortions etiology is a multi-factorial condition 
with both immune as well we non-immune causes. This study has proven a possible 
association of polymorphism IL-10 -819 C/T and the increased frequency of recurrent 
abortions and the lack of association between polymorphisms IL10-592C/A, IL6-
174G/C, IL-17 and the abortion disease in the studied group. 
 
Limitations 
The size of sample may not be large enough which weakens the ability for solid 
statistical inference. Further studies with larger sample size from different districts are 
needed to identify the association between cytokines gene polymorphisms and recurrent 
miscarriage in the Palestinian females with RM. 
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Appendix A 
 
FASTA sequences from NCBI 
Sequences of normal genotypes, and sequences of single-nucleotide polymorphism for 
our Interleukins. IL-10-592 A/C (rs1800872), IL-10-819 C/T (rs1800871), IL-17F 
(rs763780), IL-17A (rs2275913), and IL-6-174 G/C (rs1800795). 
Sequence A1: sequence of normal genotype of IL-6-174G/C, digested by NlaIII. 
TGACTTCAGCTTTACTCTTTGTCAAGACATGCCAAAGTGCTGAGTCACTAATAAAAGAAAAAAAGAAA
GTAAAGGAAGAGTGGTTCTGCTTCTTAGCGCTAGCCTCAATGACGACCTAAGCTGCACTTTTCCCCCTA
GTTGTGTCTTGCCATGCTAAAGGACGTCACATTGCACAATCTTAATAAGGTTTCCAATCAG 
 
 
Sequence A2: sequence of IL-6 -174G/C SNP rs1800795 (uncut) 
TGACTTCAGCTTTACTCTTTGTCAAGACATGCCAAAGTGCTGAGTCACTAATAAAAGAAAAAAAGAAA
GTAAAGGAAGAGTGGTTCTGCTTCTTAGCGCTAGCCTCAATGACGACCTAAGCTGCACTTTTCCCCCTA
GTTGTGTCTTGCGATGCTAAAGGACGTCACATTGCACAATCTTAATAAGGTTTCCAATCAG 
 
Sequence A3: sequence of normal genotype of IL-17A. 
TCTCCATCTCCATCACCTTTGTCCAGTCTCTATCCCCATTTTCAATTCCTTCCTCAAAACACCAAGTTGCT
TGGTAGCATGCAGGGTTGGAACATGCCTTTAACAGAAAATCTCGTGTCTCTTGAACCTAGTTATTTATTC
CTTGAGCAGAGTAGATATTCAACAAAAGAATTGTTAAATTCAATTAAATAGGATATATCTTATTATTAA
ATATTTTTTTCATTTTTTGTTTACTTATATGATGGGAACTTGAGTAGTTTCCGGAATTGTCTCCACAACAC
CTGGCCAAGGAATCTGTGAGGAAAAGAAAGATCAAATGGAAAATCAAGGTACATGACACCAGAAGAC
CTACATGTTACTTCAAACTTTTTCTTCCTCATGAACCATTAAAATAGAGCATAACTCTTCTGGCAGCTGT
ACATATGTTCATAAATACATGATATTGACCCATAGCATAGCAGCTCTGCTCAGCTTCTAACAAGTAAGA
ATGAAAAGAGGACATGGTCTTTAGGAACATGAATTTCTGCCCTTCCCATTTTCCTTCAGAAGGAGAGA
TTCTTCTATGACCTCATTGGGGGCGGAAATTTTAACCAAAATGGTGTCACCCCTGAACCCACTGCGACA
CGCCACGTAAGTGACCACAGAAGGAGAAAAGCCCTATAAAAAGAGAGACGATAGCGCTACATTTTGTC
CATCTCATAGCAGGCACAAACTCATCCATCCCCAGTTGATTGGAAGAAACAACGATGACTCCTGGGAA
GACCTCATTGGTGGTGAGTCCTGCACTAACGTGCGATGCTCTTGCTGATTTGGAC 
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Sequence A4: sequence of IL-17A SNP rs2275913. 
 
TCTCCATCTCCATCACCTTTGTCCAGTCTCTATCCCCATTTTCAATTCCTTCCTCAAAACACCAAGTTGCT
TGGTAGCATGCAGGGTTGGAACATGCCTTTAACAGAAAATCTCGTGTCTCTTGAACCTAGTTATTTATTC
CTTGAGCAGAGTAGATATTCAACAAAAGAATTGTTAAATTCAATTAAATAGGATATATCTTATTATTAA
ATATTTTTTTCATTTTTTGTTTACTTATATGATGGGAACTTGAGTAGTTTCCGGAATTGTCTCCACAACAC
CTGGCCAAGGAATCTGTGAGGAAAAGAAAGATCAAATGGAAAATCAAGGTACATGACACCAGAAGAC
CTACATGTTACTTCAAACTTTTTCTTCCTCATGAACCATTAAAATAGAGCATAACTCTTCTGGCAGCTGT
ACATATGTTCATAAATACATGATATTGACCCATAGCATAGCAGCTCTGCTCAGCTTCTAACAAGTAAGA
ATGAAAAGAGGACATGGTCTTTAGGAACATGAATTTCTGCCCTTCCCATTTTCCTTCAGAAGAAGAGA
TTCTTCTATGACCTCATTGGGGGCGGAAATTTTAACCAAAATGGTGTCACCCCTGAACCCACTGCGACA
CGCCACGTAAGTGACCACAGAAGGAGAAAAGCCCTATAAAAAGAGAGACGATAGCGCTACATTTTGTC
CATCTCATAGCAGGCACAAACTCATCCATCCCCAGTTGATTGGAAGAAACAACGATGACTCCTGGGAA
GACCTCATTGGTGGTGAGTCCTGCACTAACGTGCGATGCTCTTGCTGATTTGGAC 
 
 
Sequence A5: sequence of normal genotype of IL-17F. 
 
CACTGGTGCTCTGATGAGGAAATATGAAAAACAAATGATAGGCATATAGAATTCCAAAATGTGTAGGG
CTACACAGTCTGTGAGTACAAGCTGGGAATGCAAACAAACACCTGAAGTATTTTTAAATTATTAATACT
TTATTATATTAGCACTGAATATATTAATTTTTCTCCTAACATTTTAGATATCAAATATAAAGTGTAGTAC
ATACACACATACATTGTGAATATTTTCTGTTTCCATCCGTGCAGGTCTTATTAAGAGTCCTGTGAAGTGG
AGGGAATTGGGGGTCAGACAGGACTTGTTGCAGAGCACTGGGTAAGGAGTGGCATTTCTACAGCTTCTT
CAGCTGAGTGGATATGCACCTCTTACTGCACATGGTGGATGACAGGGGTGACGCAGGTGCAGCCAACA
GTCACCAGCACCTTCTCCAACTGGAAAGAAACAGAGCAGCCTTGGTGCTTCCTCCGGACGACCAGGGTC
TCTTGCTGGATGGGAACGGAATTCATGGAGATGTCTTCCTTTCCTTGAGCATTGATGCAGCCCAAGTTCC
TACACTGGGCCTGTACAACTTCCGAGGGGTACCGGTTGGGGTCCCAAGTGACACTGCAGGAGGAGCAA
GCCAAAGCACAATG 
 
Sequence A6: sequence of IL-17F SNP rs763780 
 
CACTGGTGCTCTGATGAGGAAATATGAAAAACAAATGATAGGCATATAGAATTCCAAAATGTGTAGGG
CTACACAGTCTGTGAGTACAAGCTGGGAATGCAAACAAACACCTGAAGTATTTTTAAATTATTAATACT
TTATTATATTAGCACTGAATATATTAATTTTTCTCCTAACATTTTAGATATCAAATATAAAGTGTAGTAC
ATACACACATACATTGTGAATATTTTCTGTTTCCATCCGTGCAGGTCTTATTAAGAGTCCTGTGAAGTGG
AGGGAATTGGGGGTCAGACAGGACTTGTTGCAGAGCACTGGGTAAGGAGTGGCATTTCTACAGCTTCTT
CAGCTGAGTGGATATGCACCTCTTACTGCACACGGTGGATGACAGGGGTGACGCAGGTGCAGCCAAC
AGTCACCAGCACCTTCTCCAACTGGAAAGAAACAGAGCAGCCTTGGTGCTTCCTCCGGACGACCAGGG
TCTCTTGCTGGATGGGAACGGAATTCATGGAGATGTCTTCCTTTCCTTGAGCATTGATGCAGCCCAAGTT
CCTACACTGGGCCTGTACAACTTCCGAGGGGTACCGGTTGGGGTCCCAAGTGACACTGCAGGAGGAGC
AAGCCAAAGCACAATG 
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Sequence A7: sequence of normal genotype of IL-10-592 A/C digested by Rsa I 
 
GGTGAGCACTACCTGACTAGCATATAAGAAGCTTTCAGCAAGTGCAGACTACTCTTACCCACTTCCCCC
AAGCACAGTTGGGGTGGGGGACAGCTGAAGAGGTGGAAACATGTGCCTGAGAATCCTAATGAAATCGG
GGTAAAGGAGCCTGGAACACATCCTGTGACCCCGCCTGTACTGTAGGAAGCCAGTCTCTGGAAAGTAA
AATGGAAGGGCTGCTTGGGAACTTTGAGGATATTTAGCCCACCCCCTCATTTTTACTTGGGGAAACTAA
GGCCCAGAGACCTAAGGTGACTGCCTAAGTTAGCAAGGAGAAGTCTTGGGTATTCATCCCAGGTTGGG
GGGACCCAATTATTTCTCAATCCCATTGTATTCTGGAATGGGCAATTTGTCCACGTCACTGTGACCTAGG 
 
 
 
 
Sequence A8: sequence of IL-10-592 A/C rs1800872 (uncut) 
 
GGTGAGCACTACCTGACTAGCATATAAGAAGCTTTCAGCAAGTGCAGACTACTCTTACCCACTTCCCCC
AAGCACAGTTGGGGTGGGGGACAGCTGAAGAGGTGGAAACATGTGCCTGAGAATCCTAATGAAATCGG
GGTAAAGGAGCCTGGAACACATCCTGTGACCCCGCCTGTCCTGTAGGAAGCCAGTCTCTGGAAAGTAA
AATGGAAGGGCTGCTTGGGAACTTTGAGGATATTTAGCCCACCCCCTCATTTTTACTTGGGGAAACTAA
GGCCCAGAGACCTAAGGTGACTGCCTAAGTTAGCAAGGAGAAGTCTTGGGTATTCATCCCAGGTTGGG
GGGACCCAATTATTTCTCAATCCCATTGTATTCTGGAATGGGCAATTTGTCCACGTCACTGTGACCTAGG 
 
 
Sequence A9: sequence of normal genotype of IL-10-819 C/T, (uncut) 
 
TCATTCTATGTGCTGGAGATGGTGTACAGTAGGGTGAGGAAACCAAATTCTCAGTTGGCACTGGTGTAC
CCTTGTACAGGTGATGTAATATCTCTGTGCCTCAGTTTGCTCACTATAAAATAGAGACGGTAGGGGTCA
TGGTGAGCACTACCTGACTAGCATATAAGAAGCTTTCAGCAAGTGCAGACTACTCTTACCCACTTCCC 
CCA 
 
 
Sequence A10: sequence of IL-10-819 C/T rs1800871, digested by Mea III. 
TCATTCTATGTGCTGGAGATGGTGTACAGTAGGGTGAGGAAACCAAATTCTCAGTTGGCACTGGTGTAC
CCTTGTACAGGTGATGTAACATCTCTGTGCCTCAGTTTGCTCACTATAAAATAGAGACGGTAGGGGTC
ATGGTGAGCACTACCTGACTAGCATATAAGAAGCTTTCAGCAAGTGCAGACTACTCTTACCCACTTCCC
CCA 
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Appendix B 
Virtual cuts of Interleukins genes sequences by different enzymes determined by 
NEBcutter software (http://nc2.neb.com/NEBcutter2/). 
 
B1: IL-6 (GG) uncutt 
 
 
B2: IL-6 (CC) 
______________________________________________________________________ 
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B3: IL-17F (CC) 
 
 
B4: IL-17F (TT) 
______________________________________________________________________ 
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B5: IL-17A (GG) 
 
 
B6: IL-17A (AA) 
______________________________________________________________________ 
 
53 
 
 
B7: IL-10 (AA) normal 
 
 
B8: IL-10 (C/T) 
______________________________________________________________________ 
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Appendix C 
 
Study Questionnaire/ English 
 
Risk factors of miscarriage: a case-control study 
 
 
Name: 
(Last, First, M.I.): 
  
Date of Birth: 
(month/day/year) 
  
Today’s Date: 
(month/day/year) 
 
 
Address: 
  
Telephone: 
 
 
Interviewee code: Status: 
 
1.Case 
 
0.Control 
 
1. At what age your menses began? ___________ 
 
2. Are your menstrual cycle spaced irregularly? ___________ 
   
3. How many live births did you have?___________ 
 
4. How many miscarriages did you have?_________ 
 
5. Please mention the gestational age/ages when you had miscarriage. ______________ 
 
6. How many stillbirths did you have? _________ 
 
7. Please mention the gestational age/ages when you had stillbirths. ______________ 
 
8. Have you had any D&C and when? ______________ 
   
 
9. How many total pregnancies (including live births, abortions, miscarriages, 
stillbirths) did you ever have? __________ 
 
10. Have you ever smoked cigarettes? (At least one cigarette)? __________ 
   
 
11. How often did you smoke before your last pregnancy? 
□1. Never 
□2.Once a month or less 
□3. Several days a month 
□4. Several days a week 
□5. Every day 
 
12. How often did you smoke during your last pregnancy? 
□1. Never 
□2.Once a month or less 
□3. Several days a month 
□4. Several days a week 
□5. Every day 
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13. How many of your household members smoked during your last 
pregnancy?___________ 
 
14. How often people smoked in the same room where you were during your last 
pregnancy? 
□1. Every day 
□2. Several days a week 
□3. Once a week 
□4. Several days a month 
□5. Once a month or less 
□6. Never 
 
15. Did you ever drink coffee? 
    
 
16. How many cups of coffee per day did you drink before your last pregnancy? 
□1.None 
□2.Less than 1 cup per day 
□3. 1-2 cups 
□4. 3-4 cups 
□5. More than 4 
 
17. How many cups of coffee per day did you drink during your last pregnancy? 
□1.None 
□2. Less than 1 cup per day 
□3. 1-2 cups 
□4. 3-4 cups 
□5. More than 4 
 
18. Have you ever been diagnosed with Chlamydia infection? __________ 
   
 
19. Have you ever had pelvic inflammatory disease? __________ 
   
 
20. Have you ever been diagnosed with uterine fibroids or polyps? __________ 
   
 
21. Have you ever been diagnosed with endometriosis? __________ 
   
 
22. Hormone laboratory tests and ultra sound scan results? __________ 
  
 
23. Your partner’s semen tests result? __________ 
  
24. Have you taken contraceptive pills? For how long? __________ 
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25. Are you complaining of any medical condition? __________ 
   
(Diabetes, High Blood Pressure, Bleeding or blood clotting disorder, Blood transfusion..etc) 
 
26. Are you presently taking any medication? __________ 
   
 
27. Has anybody in your family had any medical condition? __________ 
   
 
28. Have you been screened for Antiphospholipids, Anticardiolipin, and Rubella titer?  
    (if yes   
 
29. On average how many hours did you sleep before your last pregnancy during 24 
hours? 
□1. ≤ 8 hours    □2. ≥8 hours 
 
30. On average how many hours did you sleep during your last pregnancy during 24 
hours? 
□1. ≤ 8 hours    □2. ≥8 hours 
 
31. Did you have traumas/accidents during your last pregnancy? 
   
 
32. What was your weight before last pregnancy? ________ (kg) 
□. Don’t know   □. Refused to answer 
 
33. What is your height?________ (cm) 
□. Don’t know   □. Refused to answer 
 
34. Education: 
□1.School (less than 10 years) 
□2. School (10-12 years) 
□3.Institute/University 
□4.Postgraduate 
 
35. Are you employed? 
   
 
THANK YOU 
for your participation!!! 
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 حغٞت ؽٞبت ٗبؼذ,,, 
فٜ اىبذاٝت ّ٘د أُ ّشنشمٌ ػيٚ اى٘قج ٗاىضٖذ اىزٛ س٘ف حبزىّ٘ٔ فٜ ٍيئ ٕزا الاسخبٞبُ. 
ٕزا الاسخبٞبُ بَ٘ػ٘ػٞت ٗشفبفٞت ٕ٘ ٍغو شنشّب ٗحقذٝشّب,  حؼبئتمَب أُ إخَبٍنٌ ٗعشطنٌ ػيٚ 
فْخبئش ٕزا الاسخبٞبُ سخسبػذ اىببعزِٞ ػيٚ اسخنَبه بغزٌٖ ٗعو ٍشنيت اىبغذ اىزٛ سٞذٗس ع٘ه 
  ؼغ ػ٘اٍو خطش الاصٖبع "ب"
ٍلاعظت: اىَؼيٍ٘بث اىخٜ سٞخٌ صَؼٖب, ٗالإؽلاع ػيٖٞب لأغشاع اىبغذ اىؼيَٜ فقؾ. ٗىِ 
شٝؼٔ اٗ ٝخٌ إسبءة اسخخذاٍٖب ٗسٞخٌ عفظٖب صٞذاً ٕٜٗ ٍؼيٍ٘بث سشٝت ىِ ٝخٌ الافظبط ػِ اسٌ اىَ
 ٍؼيٍ٘بث حخض اىَشبسمِٞ  فٜ اىبغذ .. اٛ
 
 . ئيت اىخبىٞت, ٗشبمشِٝ ىنٌ حؼبّٗنٌّشص٘ ٍْنٌ الإصببت ػيٚ الأس
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 استبياٌ :يٍ عىايم خطر الاجهاض
 
 تاريخ انًيلاد: _ _ _ _ _ _ _ _ _ _ _  _ _ _ الاسى انثلاثي :_ _ _ _ _ _ _ _ _ _ _ _ _ 
 (انيىو، انشهر، انسُه)
 _ _ _ _ _ _ _ _ _ _ _ _ _  :تاريخ انيىو
 
 _ _  _ _ _ _ _ _ _ _ _ _ _ _ _:رقى انتهفىٌ
 _ _  _ _ _ _ _ _ _ _ _ _ _ _ _:انعُىاٌ
 
 _  وضع انحانة :_ _ _ _ _ _ _ _ _ _ _ _ _ 
 
 اٛ سِ بذاث ػْذك اىذٗسة اىشٖشٝت ؟ _ _ _ _ _ _ _ _ _ _ _  فٜ -1
 
  ٕو اىذٗسة اىشٖشٝت غٞش ٍْخظَٔ اٗ ٍخببػذة؟ _ _ _ _ _ _ _ _ _ _ _             -2
 لا  ّؼٌ 
 ٞذ ىذٝل؟ _ _ _ _ _ _ _ _ _ _ _ _مٌ ػذد اىَ٘اى -3
 
 مٌ ػذد عبلاث اىضٖبع ىذٝل؟ _ _ _ _ _ _ _ _ _ _ _ -4
 
 الإصٖبع ؟ _ _ _ _ _ _ _ _ _ _ _ عظو فٖٞب ٝشصٚ رمش سِ اىغَو فٜ مو ٍشة -5
 
 مٌ ػذد عبلاث ٍ٘ث اىَ٘اىٞذ داخو اىشعٌ ىذٝل؟ _ _ _ _ _ _ _ _ _ _ _ _  -6
 
 و ٍشة ػْذٍب مبُ ىذٝل ٍ٘ث اىضِْٞ داخو اىشعٌ  ؟_ _ _ _ _ _ _ ٝشصٚ رمش سِ اىغَو فٜ م -7
 
 ٕو مبُ ىذٝل اٛ ػَيٞت صشاعٞت فٜ اىشعٌ, ٍخٚ مبُ رىل ؟ _ _ _ _ _ _ _ _ _ _  _ _ -8
 لا  ّؼٌ 
مٌ ػذد ٍضَ٘ع عبلاث اىغَو (بَب فٜ رىل ٗلادة عٞت، الإصٖبع، ٍ٘ث اىضِْٞ داخو اىشعٌ)  -9
 _ _ _  ؟ _ _ _ _ _ _ _ _ _ىذٝل 
 
 ٕو سبق ىل أُ دخْج اىسضبئش؟ (سٞضبسة ٗاعذة ػيٚ الأقو) ؟ _ _ _ _ _ _  _ _ _-01
 لا  ّؼٌ 
 
 ?مٌ ػذد اىَشاث اىخٜ دخْخٜ بٖب قبو عَيل الاخٞش -11
 ٍشة ٗاعذٓ فٜ اىشٖش اٗ اقو  ابذا 
 ػذة ٍشاث فٜ الاسب٘ع  ػذة ٍشاث فٜ اىشٖش 
  مو ًٝ٘ 
 
 ؟ْبء عَيل الاخٞشمٌ ػذد ٍشاث اىخذخِٞ ىذٝل ار -21
 ٍشة ٗاعذٓ فٜ اىشٖش اٗ اقو  ابذا 
 ػذة ٍشاث فٜ الاسب٘ع  ػذة ٍشاث فٜ اىشٖش 
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  مو ًٝ٘ 
 
 ؟ _ _ _ _ _ _ _ _  _ _ _  مٌ ػذد أفشاد ػبئيخل اىزِٝ ٝذخُْ٘ خلاه فخشة اىغَو الأخٞش -31
 
خشة عَيل الاخٞش ػذد اىَشاث اىخٜ ٝذخِ بٖب اشخبص فٜ ّفس اىغشفت اىخٜ حنِّ٘ٞ بٖب خلاه ف -41
 ؟
 ٍشة ٗاعذٓ فٜ اىشٖش اٗ اقو  ابذا 
 ػذة ٍشاث فٜ الاسب٘ع  ػذة ٍشاث فٜ اىشٖش 
  مو ًٝ٘ 
 
 ٕو حخْبٗىِٞ اىفٖ٘ة ؟-51
 
 مٌ ػذد فْبصِٞ اىقٖ٘ة اىخٜ مْج حششبْٖٞب فٜ اىًٞ٘ اى٘اعذ قبو عَيل الاخٞش؟ -61
 اقو ٍِ فْضبُ فٜ اىًٞ٘ اى٘اعذ  طفش 
 فْبصِٞ 4-3  فْبصِٞ 2-1 
  4امزش ٍِ  
 
 مٌ ػذد فْبصِٞ اىقٖ٘ة اىخٜ مْج حششبْٖٞب فٜ اىًٞ٘ اى٘اعذ خلاه فخشة عَيل الاخٞش ؟ -71
 اقو ٍِ فْضبُ فٜ اىًٞ٘ اى٘اعذ  طفش 
 فْبصِٞ 4-3  فْبصِٞ 2-1 
  4امزش ٍِ  
 
 ٕو سبق  أُ حٌ حشخٞظل بؼذٗٙ اىنلاٍٞذٝب؟ _ _ _ _ _ _ _ _ _ _ _ _ _  -81
 لا  ّؼٌ 
 
 ٕو سبق ٗ مْج حؼبِّٞ ٍِ اىخٖبة فٜ اىغ٘ع؟ _ _ _ _ _ _  _ _ _ _ _ _  -91
 لا  ّؼٌ 
 
 ٕو سبق ىل أُ حٌ حشخٞظل ببلأٗساً اىيٞفٞت اىشعَٞت أٗ الاٗساً اىغَٞذة ؟ _ _ _ _ _ _ _  _-02
 لا  ّؼٌ 
 
 ٕو سبق ىل أُ حٌ حشخٞظل ببىخٖبة بطبّت اىشعٌ ؟ _ _ _ _ _ _ _ _ _ _ _  _-12
 لا  ّؼٌ 
 
 ّخبئش اىفغ٘طبث اىَخبشٝت ىيٖشٍّ٘بث ٗ ٍسظ اىظ٘ث (الاىخشاسبّٗذ)؟ _ _ _ _ _ _ _ _ _  -22
 لا  ّؼٌ 
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 غٞش ؽبٞؼٞت  ؽبٞؼٞت 
 
 ّخٞضت اىفغض اىَخبشٛ ىيسبئو اىَْ٘ٛ ىيضٗس ؟ _ _ _ _ _ _ _ _ _ _ _ -32
 غٞش ؽبٞؼٜ  ؽبٞؼٜ 
 
 ٕو اسخؼَيج عب٘ة ٍْغ اىغَو ؟اىٚ ٍخٚ ؟ _ _ _ _  _ _ _ _ _ _ _  -42
 لا  ّؼٌ 
 
 ٕو حشنخنِٞ ٍِ اٛ عبىت ٍشػٞت ؟ _ _ _ _ _  _ _ _ _ _ _ _ -52
 (ٍشع اىسنشٛ، ٗاسحفبع ػغؾ اىذً، ّضٝف أٗ اػطشاة فٜ اىذً, حخزش اىذً, ّقو دً, اىخ) 
 لا  ّؼٌ 
 
 ٕو حبخزِٝ اٛ ّ٘ع ٍِ اّ٘اع الادٗٝت فٜ اىفخشة اىغبىٞت ؟ _ _ _  _ _ _ _ _ _ _-62
 لا  ّؼٌ 
 
 اٛ ٍِ افشاد ػبئيخل ٍِ عبىت ٍشػٞت  ؟_ _ _ _  _ _ _ _ _ _ _  ٕو ٝؼبّٜ-72
 لا  ّؼٌ 
 
 nipiloidracitna ,sdipiolohpsohpitna ٕو سبق ٗ خؼؼخٜ ىفغض اىغظبت الاىَبّٞت؟  -82
 لا  ّؼٌ 
 :ارا مبّج الاصببت ّؼٌ 
 غٞش ؽبٞؼٜ  ؽبٞؼٜ 
 
 َيل الاخٞش ؟سبػٔ قبو بذاٝت ع 42فٜ اىَخ٘سؾ مٌ ػذد سبػبث ٍّ٘ل خلاه اه  -92
 سبػبث 8امزش ٍِ   سبػبث 8اقو ٍِ  
 
 سبػت ؟ 42فٜ اىَخ٘سؾ مٌ ػذد سبػبث اىًْ٘ خلاه اىغَو الاخٞش فٜ اه   -03
 سبػبث 8امزش ٍِ   سبػبث 8اقو ٍِ  
 
 
 ?ٕو حؼشػج ىظذٍبث / ع٘ادد أرْبء اىغَو الأخٞش .13
 لا  ّؼٌ 
 
 _ _  _ _ _  مٌ مبُ ٗصّل قبو اىغَو الأخٞش (مغٌ ) ؟ _ _ _  _ -23
 سفغ الاصببت   لا اػشف  
 
 ٍب ٕ٘ ؽ٘ىل (سٌ) ؟_  _ _ _ _ _ _ _ _ -33
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 سفغ الاصببت   لا اػشف  
 
 :ٍب اىَسخ٘ٙ اىخؼيَٜٞ   -43
 سْٔ) 21-01ٍذسست (  سْ٘اث) 01ٍذسست (اقو ٍِ  
 دساسبث ػيٞب  ٍؼٖذ\صبٍؼت 
 
 ٕو اّج ٍ٘ظفت ؟ -53
 لا  ّؼٌ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ٌشنشا ىَشبسمخن
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Consent form: 
Here I certify that I have voluntarily participated in this study by filling up this 
questionnaire and donating a blood sample and authorize the researcher to use the above 
data and blood sample for scientific research only. 
Signature:                                                                                 Date: 
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و الاجهاض انًتكرر غير  )snikuelretnI(انعلاقه بيٍ تعذد الاشكال انجيُي نلاَترنىكيُات 
 انًبرر بيٍ َساء انضفه انغربيه.
 اعذاد: َيفيٍ َظاو عرفات صب نبٍ
 اشراف: د. رسًي ابى حهى
 نًهخص:ا
) ىو فقدان الحمل مرتين أو أكثر قبل الأسبوع العشرين من MRالإجياض المتكرر ( مقدمه: 
٪ من النساء في 4-2، وىو أحد أكثر مضاعفات الحمل شيوًعا والتي تصيب ما يصل إلى الحمل
،  عن العديد من عوامل مساىمو في خطر الاصابو بالاجياض المتكررسن الإنجاب. تم الكشف 
ت المرضية في . إن المسببا لعيوب الوراثية والجياز المناعي والغدد الصماء والتشريحيةمثل ا
، ولكن تم الافتراض بأن نسبة من  ٪ من حالات الاجياض المتكرر مجيولة الاسباب50حوالي 
 قد تكون ناجمة عن أسباب مناعية.ىذه الخسائر المتكررة لمحمل 
 
اوني بين نظام المناعة الأمومي ومستضد الجنين ، ويؤدي أثناء الحمل الطبيعي ، ىناك تفاعل تع
 لمجنين مما يؤدي إلى فقدان الحمل.  النظام المناعي إلى رفض الجسم فشل ىذا
، مع أنماط فريدة  2hTو  1hT ) إلى hTالمساعدة ( بعد مواجية المستضد ، تتمايز خلايا تي
ات جزئًيا لسيطرة جينية ، ويمكن تغيير . تخضع مستويات إنتاج السيتوكيناتمن إنتاج السيتوكين
تعبير الجينات باختلاف النوكميوتيد. وقد أظيرت العديد من الدراسات أن السيتوكينات تمعب دورًا 
مع الحمل الطبيعي ،  2hTرئيسيًا في الظواىر التناسمية ، حيث ارتبطت الاستجابة السائدة لمـ 
  مرتبطة بفشل الحمل. 1hTوكانت استجابة 
بفقدان  6-LIو FNT ,71-LIمثل في الرحم دة للالتيابات لسيتوكينات المؤيارتبط تعبير اوقد 
تحمي من الإجياض الناجم عن  01-LIالسيتوكينات المضادة للالتياب مثل  الأجنة.  أما
 لالتياب. ا
 C / A 290-المضادة للالتيابات ( 01-LIالبحث في علاقة تعدد الأشكال الجيني ل الاهداف: 
 / C 471( 6-LIو  F71-LIو  A71-LIالجينات السيتوكينية  من ثنان) ، و T / C 918-، 
مقارنة  المواليو للالتيابات عند النساء الفمسطينيات المواتي يعانين من الاجياض المتكرر) G
 ء الاصحاءبالنسا
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امرأه  00امرأه من مناطق مختمفو من الضفة الغربيو,  157شممت ىذه الدراسة المواد: الطرق و 
امرأه لا يعانين من اي مشاكل متعمقو  20و  ،لاجياضات المتكرره بدون سبب محدديعانين من ا
تطوعات, ثم تصنيف ممن عينات دم النساء ال)AND( حيث تم استخلاص الحمض النوويبالحمل. 
  )RCP(جينات), باستخدام تفاعل سمسمة البوليمرية 0ىذه العينات بتحميل جينات الدراسو (
 باستخدام انزيمات القطع المتخصصو لكل جين منيم. ،PLFR(و(
-01LI T / C في الجين لتعدد الأشكال وجود ارتباط عال  ىذه الدراسو أثبتت النتائج: 
 وعدم وجود ارتباط بين تعدد الأشكال بين النساء الفمسطينيات وزيادة تواتر الإجياض المتكرر918
ومرض الإجياض في مجموعة  LI-71و  6LI-G471C/  و 01LI-A / C295 في الجينات
 الدراسة.
امل المرضية المسببة للإجياض العديد من العو  ، وانماد عامل جيني واحد فقطلا يوج :اتالاستنتاج
العلاقة بين العوامل الوراثية  ة السبب. إذا تم توضيحمجيول % منيا50ىناك حوالي  .المتكرر
قد تمثل  الأشكال المتعددة لمجينات الوراثية لمسايتوكاينات، فإن يواضطرابات الجياز المناع
علامات لاختيار الخيارات العلاجية ولتقديم المشورة لممرضى الذين يعانون من الإجياض التمقائي 
 المتكرر.
التي أجريت في مناطق مختمفو من العالم حول  نتائج الدراسات السابقة ىناك اختلافات كبيرة في
لافات العرقية لمجموعات الدراسة, بالاضافة الى عدد كن تفسير ذلك بسبب الاختىذا الموضوع, يم
  المتغيرات المختمفة التي يتضمنيا كل بحث.
اول دراسة في الضفة الغربية تبحث في العلاقة بين مرض  ىي بحدود معرفتي ىذه الدراسة
و يمكن اعتبارىا داعمة  ،ذكورةتعدد الاشكال الجيني للانترلوكينات المالاجياض المتكرر التمقائي و 
تحتاج لدراسات سابقة في نفس المجال, و مع ذلك تبقى الالية الحقيقيو ليذه العلاقة غير معروفة و 
 الى المزيد من البحث.
  
 
